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ABSTRACT

The clinical use of methylphenidate for pre-school

aged children has become increasingly common over the last

decade.,

However, little is known about the long-term

effects of stimulant medication on this age group.

Developmental studies in rodents suggest that early
methylphenidate exposure, may alter later reward to drugs of

abuse and cause alterations in neuronal functioning.

These

studies have generated conflicting results, with some
studies suggesting that methylphenidate decreases later
drug reward while other studies indicating methylphenidate
increases later drug reward.

The present study examined

the effect of preweanling methylphenidate exposure on later

drug reward.

To this end, we examined the induction,

extinction, and reinstatement of morphine-induced
conditioned place preference (CPP) in rats that received

methylphenidate pretreatment during the preweanling period.
It was predicted that rats pretreated with methylphenidate

would show a greater preference for morphine.

In addition,

methylphenidate pretreated rats were predicted to
extinguish more slowly and show a greater morphine-induced

CPP after reinstatement.

The results of our study indicate

that preweanling methylphenidate exposure does affect

iii

morphine CPP.

While methylphenidate pretreated rats did

not show an initial preference for morphine, the other two

Rats pretreated with the high

predictions were supported.

dose of methylphenidate were slower to extinguish as

compared to rats pretreated with the low dose of
methylphenidate or saline.

In addition, CPP was more

easily reinstated in rats pretreated with the high dose of

methylphenidate than rats pretreated with the low dose of
methylphenidate or saline.

These findings have

implications for the use of methylphenidate in pre-school
aged children as a risk factor for vulnerability towards
drug abuse.

Our findings indicate that early

methylphenidate exposure increases later drug reward,

therefore increasing vulnerability towards drug abuse.
may be more susceptible towards drug addiction because

drugs of abuse become more rewarding following stimulant

treatment in early childhood.
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CHAPTER ONE
STIMULANT MEDICATION IN

EARLY DEVELOPMENT

Attention-Deficit/
Hyperactivity Disorder

Attention-deficit hyperactivity disorder (ADHD) is the
most common neuropsychiatric diagnosis given to children,
with currently 3% - 5% of children meeting the DSM-IV

diagnostic criteria for the disorder (Kwasman, Tinsley &

Lepper, 1995) . The disorder disrupts central nervous system
regulation of attention span, impulsiveness, and motor

activity, and presents significant challenges to affected

children, their families, and the school system (Kwasman et
al., 1995).

Given the high prevalence of this problem,

along with its major impact on quality of life, it is
imperative that we study its possible etiologies, clinical
manifestations, and treatments (Palfrey, Levine, Walker &

Sullivan, 1985).

Stimulant Medication to
Treat Attention-Deficit/
Hyperactivity Disorder

Outpatient visits devoted to ADHD increased from 1.6

to 4.2 million per year during the years of 1990-1993
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(Swanson, Lerner & Williams, 1995) .

During those visits,

90% of the children were given prescriptions, 71% of which

were for the stimulant, methylphenidate.

Methylphenidate

production in the United States increased from 1,784 kg to
5,110 kg during the same time period, so that over 10

million prescriptions for methylphenidate were written in
1996 (Vitiello & Jensen, 1997).
Stimulant medication remains the most common way to

treat ADHD.

One study surveyed randomly selected members

of the American Academy of Pediatrics (AAP) concerning ADHD

assessment and treatment (Copeland, Wolraich, Lindgren,
Millch & Woolson, 1987).

The respondents in the survey

reported that their most frequently used therapy for ADHD

was methylphenidate.

In a follow up to this study,

children, physicians, parents and teachers were intensively

interviewed in an effort to ascertain the treatment used

for children with ADHD (Wolraich et al., 1990).

Findings

from this study indicated that stimulant medication,
particularly methylphenidate, was the treatment of choice

for ADHD by family practice physicians.

More recently, in

a national survey of 380 members of the American Academy of
Pediatrics, respondents reported that 50% of their patients
had not received educational testing before they wrote
2

prescriptions for methylphenidate and similar drugs, and
even fewer of their patients received psychological testing

(Kwasman et al., 1995).

In terms of medications that the

pediatricians reported using in treating ADHD,
methylphenidate was reported as being prescribed 97.6% of

the time (Kwasman et al., 1995).

Finally, in the only

study that used a nationally representative sample of
patient records from office-based physicians, it was found
that over 26% of the children receiving psychotropic
medications were not scheduled for follow-up visits and

only 36% were provided any counseling or psychotherapy

(Kelleher, Hohmann & Larson, 1989).

The 1996 Practice

Parameters for the Assessment and Treatment of Children,

Adolescents, and Adults with ADHD cite three "cornerstones"

of treatment: parent support and education, appropriate
school placement, and pharmacology.

However, as evidenced

in the research, it appears that stimulant medication is
the predominant and preferred method of treatment for ADHD,

to the extent that other treatment modalities have been
neglected.

Because stimulant medication is prescribed so

readily for ADHD, it is important that the possible
aversive long-term consequences be examined.
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Stimulant Medication
■ Effectiveness

Although there are few long-term studies, stimulant
medication has been proven effective in reducing ADHD
symptoms.

Stimulants improve disruptive ADHD behaviors in

the home, classroom, and playground (Solanto, Arnsten &

Castellanos, 2001).

At home, stimulants improve compliance

and parent-child interactions (Whalen et al., 1989).

In

the classroom, stimulants increase on-task behavior and
decrease interrupting and restlessness (Abikoff &

Gittelman, 1985).

On the playground, stimulants reduce

covert aggression (Hinshaw, Heller & McHale, 1992), overt

aggression (Gadow, Nolan, Sverd, Sprafkin & Paolicelli,

1990), and symptoms of conduct disorder (Klein et al.,

1997) and increase attention during sports (Pelham et al.,
1990).

Stimulants decrease impulsive responding and

response variability on cognitive tasks (Tannock, Schachar
& Logan, 1995); increase accuracy of performance, improve

sustained attention, short-term memory, and reaction time
(Hinshaw, Henker, Whalen, Ehrardy & Dunnington, 1989).

In

addition to treating ADHD symptoms, stimulant medications
are beneficial in treating other medical conditions, such

as narcolepsy and depression (Goldman, Genei, Bazman &
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Stanetz, 1998).

Because stimulant medication is so

successful in reducing ADHD symptoms, it is understandable
why physicians use it as the predominant way to treat ADHD.
The general consensus in the medical community is that the

effectiveness of stimulant medication in treating ADHD
However, because the possible

outweighs its side effects.

long-term aversive effects have not been studied
thoroughly, it is important that research continue to
examine this possibility.

One major concern is whether

stimulant treatment produces neurotoxic effects that would

later increase vulnerability towards drugs of abuse.

Preschool-Aged Children
and Attention-Deficit/
Hyperactivity Disorder

The signs and symptoms of ADHD are now believed to be
evident before the age of 3 (Solanto et al., 2001).

Even

though ADHD-related behaviors displayed by preschool age
children resemble behaviors among older ADHD patients, the

diagnostic manuals give little guidance about the validity
of ADHD diagnosis in the preschool years.

School-age norms

gathered on standard teacher global rating forms, such as

the Conners Teacher Questionnaire (CTQ), have not included
preschoolers until recently (Solanto et al., 2001).
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For

many reasons, the clinical diagnosis of ADHD in preschool

children is challenging.

The first problem in diagnosis is

the nonspecificity of ADHD symptoms in the 2- to 5-year old

range.

The core symptoms of ADHD - inattention,

impulsivity, and overactivity are common daily behaviors of
most preschool aged children.

Studies have shown that up

to 40% of children by the age of 4 years have enough
problems with inattention to cause concern to their parents

and preschool teachers (Palfrey et al., 1985).

Yet studies

also show that the vast majority of these concerns are
short-lived and generally diminish within 3 to 6 months.
Even among those children whose symptoms are .severe and

frequent enough to justify a diagnosis of ADHD in the
preschool years, only 48% will have the same diagnosis by

later childhood or adolescence.

These findings suggest

that the appearance of significantly inattentive or

overactive behaviors by age 3 to 4 years, by themselves, is
not indicative of a persistent pattern of ADHD in later
childhood or adolescence in at least 50% of preschool

children (Barkley, 1998).

However, there are those

preschool age children who do display ADHD symptoms and do
warrant the diagnosis and treatment for ADHD.

Approximately 5% to 10% of preschoolers with parental or
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teacher concerns about inattention eventually develop a
pattern of persistent inattention consistent with ADHD by
the second grade (Palfrey et al., 1985).

One study

characterized a sample of preschool aged children as either
'true' hyperactive or 'situationally' hyperactive

(Campbell, Endman & Bernfield, 1977).

'True' hyperactive

children were characterized by cross-situational high
activity while 'situationally' hyperactive children were

those who were situation-specific hyperactive, with their
hyperactivity being observed only in the home.

They found

that children classified as 'true' hyperactive in the

preschool years continued to manifest problems in
elementary school as measured by classroom observation and

teacher ratings.

In assessing preschoolers who display

significant attentional or behavioral difficulties, the
clinical task is to distinguish between the 5% to 10% who
will develop ADHD and the 90% to 95% who have

developmentally appropriate and temporary symptoms of ADHDlike symptoms from other causes. Thus, the degree of ADHD
symptoms, their pervasiveness across settings, and their

duration determine which children with early-onset
difficulties are likely to show a chronic course of their
ADHD symptoms throughout development (Barkley, 1998).
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Preschool-Aged Children
and Stimulant Medication

Although research has indicated that diagnosing ADHD
in the early years is difficult, the clinical use of
stimulant medication for 3- to 6- year old preschool
children who meet the diagnostic criteria for ADHD is

becoming more common.

There is a growing concern about the

increasing numbers of young children being treated with
stimulants (Safer & Zito, 1996).

Unfortunately, there is a

lack of research.assessing stimulant effects on the very
young and developing brain.
Since 1975, only nine double-blind placebo-controlled
studies have assessed the efficacy of stimulants for ADHD

in preschool children 1.8 to 6 years of age (Connor, 2002).

All nine studies assessed ADHD children on methylphenidate.
No other type of stimulant (Adderall, Concerta,
dextroamphetamine, or pemoline) has been assessed under

controlled conditions in the preschool age range.

Studies

have assessed the efficacy of methylphenidate in

alleviating ADHD symptoms by using reports from parents,

caregivers, and nursery school personnel.

Only one

controlled study has assessed outcome using laboratory
psychological tests in this age group (Byrne, Bawden,
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DeWolfe & Beattie, 1998).

The two neuropsychological

domains assessed in methylphenidate drug studies of

preschool ADHD children are cognition and attention span.
Behavioral domains assessed include
hyperactivity/impulsivity and interpersonal interactions.

In eight of the nine controlled studies, 89% report
methylphenidate as effective in treating the symptoms of

ADHD in preschool children (Barkley, Karlsson, Strzelecki &
Murphy, 1984; Barkley, 1988; Byrne et al., 1998; Conners,

1975; Cunningham, Siegel & Offord, 1985; Handen, Feldman &

Lurier, 1999; Mayes, Crites, Bixler, Humphrey & Mattison,
1994; Monteiro-Musten, Firestone & Pisterman, 1997).

Three

studies report improvements across all domains including

behavioral, interpersonal, and cognitive functioning (Byrne

et al., 1998; Cunningham et al., 1985; Monteiro-Musten et
al., 1997).

Improvement is reported in two studies

specifically assessing behavioral domains (Conners, 1975;

Mayes et al., 1994) and in two studies investigating
interpersonal interactions in ADHD preschoolers' (Barkley et

al., 1984; Barkley, 1988).
However, not all methylphenidate studies report
benefits of ADHD children in-the 3- to 6-year old range.

One controlled study found mixed results with many reported
9

side effects using methylphenidate in preschool ADHD

children (Schleifer et al., 1975).

One study randomly

assigned children to either methylphenidate, cognitive
behavioral therapy, or no treatment.

Results did not

demonstrate treatment benefits for either methylphenidate

or behavioral therapy relative to no treatment for 24 ADHD
preschool children (Cohen, Sullivan, Minde, Novak & Helwig

1981).

Another controlled study, although reporting

positive effects of drugs on ADHD symptoms in preschoolers,
noted a large variability in individual responses (Conners,

1975).

Although not all studies agree, these controlled

studies indicate that methylphenidate in the preschool age

range is beneficial in the treatment of ADHD.
However, there are considerable limitations in the

research literature.

The first limitation is the small

number of methodologically controlled studies (nine) and
the small sample sizes of studies assessing stimulant

efficacy for ADHD in the preschool years.

Of the 5768

children, adolescents, and adults studied under controlled

conditions in stimulant drug trials for ADHD, only 206
subjects are in the preschool-age range (Spencer et al.,
1996).

In order to draw conclusions about the safety and
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efficacy of stimulants for preschool ADHD children, much

more controlled research is necessary.
Also, the duration of methylphenidate drug trials in

the preschool years has been brief.

The average length of

methylphenidate therapy in these studies is only a little
longer than 4 weeks.

Because ADHD is commonly a chronic

neuropsychiatric disorder that may last several years, and
that preschool ADHD children may be treated with stimulants

for many years, there is a need for studies assessing long
term stimulant treatment safety and efficacy when stimulant
medication for ADHD is given early in development (Connor,
2002) .

Stimulant Side Effects in
At tention-Deficit/
Hyperactivity Disorder
Preschoolers

As the diagnosis of ADHD and use of stimulant
medication become more common in the preschool years, there

is concern about the possible side effects of treating very

young children with these medications.

Because studies

done in the 1970's showed many side effects in ADHD

preschoolers treated with methylphenidate, the general
clinical opinion has been that very young ADHD children

experience more frequent and possibly more severe side
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effects of stimulant medication than older ADHD elementary-

school children (Conners, 1975; Schleifer et al., 1975).

Recently, researchers have begun to systematically

evaluate side effects of stimulant drug treatment in ADHD
preschoolers in methodologically controlled designs.

There

are two studies presently available (Barkley et al., 1990;

Firestone, Monteiro-Musten, Pisterman, Mercer & Bennett,
1998).

These two studies used the same side-effects rating

scales, methylphenidate dosing, and methodological design.
One study assessed methylphenidate side effects on a 17-

item rating scale in school-aged children 5- to 13-years
old (Barkley et al., 1990).

The other study investigated

methylphenidate on the same 17-item rating scale in
preschool children 4-to 6-years of age (Firestone et al.,

1998) .

Doses of methylphenidate used in both studies were

placebo, 0.3 mg/kg and 0.5 mg/kg given twice daily.

Both

studies used a blinded, placebo-controlled crossover design

in which children were randomized to each drug condition
for 7 to 10 days before crossing over into the next drug

condition.
By comparing these two studies, several points about

methylphenidate side effects can be noted.

First, ADHD

children receiving placebo were found to have many of the
12

behavioral side effects attributable to methylphenidate.
Second, methylphenidate side effects in preschool and

school-aged children are generally described as mild.

Third, this comparison of the two studies suggests the
possibility that methylphenidate side effects reported as
severe by parents may be slightly increased in preschool
ADHD children (10%) as compared to older children (3.6%).

Fourth, behaviors reported as side effects may actually
improve on drug treatment (i.e. insomnia, anxiety, and

irritability in ADHD preschoolers).

Lastly, except for

appetite suppression, side effects reported as significant
in younger ADHD children (sad, nightmares, drowsy, talks

less, uninterested) are not the same side effects reported
as significant for older school-aged ADHD children
(insomnia, stomachache, headache).

This suggests that

type, frequency, and/or severity of methylphenidate-induced
side effects may change with age and development.
Before conclusions can be made, much more research is

needed that compares safety and efficacy of stimulants
across development.

Unanswered questions involve the long

term safety of stimulant medication for preschool-aged
children and the longer duration of treatment over the
developing years..

It is important to consider the
13

possibility of adverse effects of stimulant medication on
the developing brain.

The CNS structures believed to be

important in the regulation of attention span and motor

activity include the prefrontal cortex, thalamus, basal
Many of these

ganglia, and cerebellum (Solanto, 1998).

structures mature well after birth.

Thus, stimulant

treatment during early development may alter the

development of these important brain structures.

One area

of particular interest is whether early methylphenidate

treatment would alter the brain in such a way as to
increase later vulnerability to drugs of abuse.

Stimulant Treatment as a
Risk for Substance Abuse
Disorder

It is difficult to investigate within the human
population whether stimulant treatment for ADHD is
associated with adult substance abuse.

One reason is that

ADHD, itself, is believed to be a risk factor that

predisposes people to develop alcohol and other drug
problems (Lynskey & Hall, 2001).

Evidence supporting a

role for ADHD in substance abuse comes from studies
reporting elevated rates of childhood ADHD among people

seeking treatment for opiate, cocaine, and other substance
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abuse disorders (Carroll & Rounsaville, 1993).

In one

study, 35% of 298 people who sought treatment for cocaine

abuse met the criteria for childhood ADHD (Carroll &
Rounsaville, 1993).

Those who reported childhood ADHD were

younger at presentation for treatment and reported earlier
onset of cocaine abuse, more frequent and intense cocaine

use, higher rates' of alcoholism, and higher rates of
previous treatment than those who did not report ADHD.

In

a longitudinal study, a sample of children referred to
treatment for problems of inattention and hyperactivity
were later assessed at age 18 (Mannuzza, Klein, Bessler,
Malloy & LaPadula, 1998).

As part of this study, subjects

with ADHD were compared to a matched control group who did
not meet the criteria for ADHD.

Those with ADHD were at a

heightened risk for antisocial personality disorder and
non-alcohol substance abuse disorder.
Another confounding variable in examining the
relationship between stimulant treatment for ADHD and
substance abuse is the co-morbidity between ADHD and other

behavioral disorders.

There is a large body of literature

showing a- high degree of correlation between attentional

difficulties and conduct problems (Lynskey & Hall, 2001).

One study reported that nearly 90% of a sample of 128

15

clinic-referred children diagnosed with ADHD also met life
time criteria for co-morbid conduct or oppositional
disorder (Biederman, Wilens, Mick, Spencer & Faraone,
1999).

Children who develop conduct disorders are at

heightened risks for a broad range of adverse outcomes in

adolescence and later life, including increased rates of
substance use and substance use-related problems.

The

linkages between early attentional difficulties and later
substance use may therefore reflect the associations

between ADHD and conduct disorder and those between conduct

disorder and later substance abuse (Lynskey & Hall, 2001).
Despite the difficulties presented to researchers, a

limited amount of research has investigated the
relationship between stimulant treatment for ADHD and

substance abuse.

The research in this area has produced

controversial results (Biederman et al., 1999; Lambert &
Hartsough, 1998; Levin, Evans, McDowell & Kleber, 1998).

Some research suggests that stimulant treatment decreases
the risk of developing a substance abuse disorder while

other research suggests that stimulant treatment increases
the risk of developing a substance abuse disorder.

study supporting the theory that stimulant treatment
reduces the risk of drug abuse reported that

16

One

methylphenidate treatment for ADHD not only reduced ADHD

symptoms but also ■ cocaine use in a sample of individuals
with co-morbid ADHD and cocaine dependence (Levin et al.,

1998).

Subjects reported reductions in .attention

difficulties, hyperactivity, .and impulsivity.

In addition

self-reported cocaine use and craving decreased
significantly.

These findings have been supported by

results of a study of substance, abuse in young people with
ADHD (Biederman et al., 1999).

In the study, the

cumulative incidence of substance abuse disorders between

medicated subjects with ADHD, non-medicated subjects with
ADHD and children without ADHD were followed-up for a
period of 4 years.

Those subjects with ADHD who received

medication were much less likely than non-medicated ADHD
subjects to develop a substance abuse disorder.
Specifically, medication was associated with an 85%

reduction in risk of developing a substance abuse disorder
Additionally, those subjects who received medication were

at approximately the same risk for developing a substance
abuse disorder as the non-ADHD controls..
One study obtained results that support the theory
that stimulant treatment for ADHD increases the risk of

substance abuse (Lambert & Hartsough, 1998).

17

In the study

subjects were divided into three subgroups.

One was

comprised of ADHD subjects who had received treatment with

methylphenidate.

A second group of subjects had been

diagnosed with ADHD, but had not received treatment with

methylphenidate or other CNS stimulants.

A third group was

comprised of age-matched controls who did not have ADHD.

Frequency of lifetime cocaine use was measured.

The

medicated ADHD subjects showed the highest percentage of

cocaine abuse, as indicated by DSM-III-R diagnosis, double

that of either the non-medicated subjects or the agematched controls.

In addition, the study examined

differential rates of adult smoking among the ADHD subjects
with different stimulant medication histories.

It was

found that those ADHD subjects who had used stimulant
medication for a year or more had a significantly higher

rate of daily smoking than subjects who had no history of
stimulant medication.

As evidenced by research using human

subjects, it is still unclear as to whether stimulant
treatment for ADHD increases or decreases the risk of

substance abuse.

In addition, interpretation of this

research is challenging since it is difficult to factor out

the variation between the medicated and non-medicated ADHD

subjects.

Because of this, it is important that animal
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studies examining the relationship between stimulant
treatment and substance abuse be conducted.
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CHAPTER TWO
NEUROTOXICITY OF

AMPHETAMINES

Neurotoxic Potential of
Methylphenidate

Most evidence supports the use of amphetamine-like
stimulants, particularly methylphenidate, as the best
available pharmacotherapy in the treatment of Attention-

deficit hyperactivity disorder (ADHD).

While the

therapeutic effects of methylphenidate are well-documented,
little is known about the possible neurotoxic consequences
of exposure to the drug.

In particular, the question

remains whether methylphenidate, like other amphetamines,
produces toxic effects on brain monoamine systems.

Methylphenidate acts similarly to other amphetamines in
that it enhances dopaminergic transmission.

Methylphenidate binds to the dopamine transporter and

inhibits dopamine uptake with a potency similar to that of
cocaine (Kuczenski & Segal, 1997).

While the toxic

effects of amphetamines have been known for quite some

time, very few studies have examined the neurotoxic

potential of methylphenidate. Those that did evaluate
methylphenidate's potential for neurotoxicity did not find
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that it produced long-lasting changes in brain monoamine

systems (Zaczek, Battaglia, Contrera, Culp & DeSouza, 1989;
Yuan, McCann & Ricaurte, 1997).

While the results of these

studies suggest that methylphenidate lacks neurotoxic
potential, much evidence has been generated regarding the
neurotoxic action of amphetamine and related drugs.

Evidence for Amphetamine
Neurotoxicity

Studies have revealed several markers of amphetamineinduced neurotoxicity on dopamine and serotonin systems.
One such marker is a reduction in striatal tyrosine

hydroxylase activity.

Tyrosine hydroxylase plays a major

role in the synthesis of dopamine.

It is the rate-limiting

enzyme in the production of L-DOPA, the precursor to
dopamine.

Methamphetamine administration has been found to

decrease tyrosine hydroxylase activity in rat striatum

(Koda & Gibb, 1973).
In addition to reducing striatal tyrosine hydroxylase,
an abundance of research has shown that amphetamine causes

long-lasting depletions of dopamine and its metabolites in
the striatum (Abekawa, Ohmori & Koyama, 1994; Cass, 1997;

Chapman, Hanson, Kesner & Keefe, 2001; Friedman, Castaneda
& Hodge, 1998; O'Dell, Weihmuller & Marshall, 1991;
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Ricaurte, Guillery, Seiden, Schuster & Moore, 1982;
Ricaurte, Schuster & Seiden, 1980; Robinson, Yew, Paulson &
Camp, 1990).

Repeated high doses of methamphetamine have

been found to produce long-term depletions of dopamine in

rat brain (Ricaurete et al., 1980).

In addition, repeated

administration of methamphetamine results in marked
decreases in extracellular concentrations of dopamine

metabolites, dihydroxyphenylacetic acid (DOPAC) and

homovanillic acid (HVA) in rat striatum (Abekawa et al.,
1994; Ricaurte et al., 1982).
Additional evidence demonstrating the neurotoxicity of

amphetamines comes from numerous studies that have shown

that amphetamine reduces number of dopamine uptake sites
(Jonsson & Nwanze, 1982; Nwanze & Jonsson, 1981; Steranka &

Sanders-Bush, 1980; Wagner, Ricaurte, Johanson, Schuster &
Seiden, 1980; Wagner, Ricaurte, Seiden, Schuster, Miller &
Westley, 1980).

In one study, the effect of

methamphetamine on number of dopamine uptake sites in the

striatum was examined (Wagner et al., 1980).

Results

showed that rats treated with methamphetamine had

significant decreases in total number of dopamine uptake
sites (Vmax) as compared to saline treated rats.

The

affinity of residual sites (Km) of methamphetamine treated
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and saline treated rats was not significantly different.
This indicates that reduction in dopamine is caused by a

decrease in dopamine uptake site number and not a decrease
in uptake site affinity.

Additional research has shown

that amphetamine, in addition to methamphetamine, produces
a loss of dopamine uptake sites in the striatum (Wagner,

Ricaurte, Johanson et al., 1980).

The results of these two

studies suggest that amphetamine and its analogs have toxic
interactions with dopaminergic neurons resulting in longlasting alterations of the dopaminergic system.

These

results are consistent with the hypothesis that there is

dopamine terminal loss after high doses of methamphetamine
treatment.

In addition to many studies indicating that
amphetamines exert long-lasting neurotoxic effects on

dopamine neurons, there is also anatomical evidence that
dopamine nerve terminal degeneration follows amphetamine

administration.

Degeneration of nerve terminals has been

found in the striatum of methamphetamine-treated rats
(Ricaurte et al., 1982).

There was, however, no evidence

that dopamine cell bodies that give rise to these terminals

were destroyed.

This indicates that the toxic effect of

methamphetamine is largely, if not exclusively, on dopamine
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nerve terminals.

In another study, to determine if this

terminal degeneration induced by amphetamine was
dopaminergic, the long-lasting dopamine depletion produced

by methamphetamine was blocked with alpha-methyl-para

tyrosine (aMPT)

(Ricaurte, Seiden & Schuster, 1984).

No

evidence of terminal degeneration was found in the striatum
of any of the rats that were administered methamphetamine
in combination with aMPT.

The fact that preventing

dopamine synthesis and depleting dopamine blocks
degeneration induced by methamphetamine administration

provides evidence that the degeneration is dopaminergic.
Lastly, methamphetamine treatment has been found to result
in swollen axons in the striatum (Lorenz, 1980).

Swollen

axons in the striatum are indicative of increased

neurotransmitter content.

Other neurotoxins such as 6-

hydroxydopamine (6-OHDA) also produce swollen, distorted

axons (Malmfors & Sachs, 1968).

The present morphological

findings suggest that methamphetamine damages dopamine

nerve terminals selectively in the striatum.

Free Radicals Theory of
Amphetamine Neurotoxicity

Methamphetamine and amphetamine are selectively
neurotoxic to dopamine and serotonin nerve terminals in the
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central nervous system (Seiden & Sabol, 1996).

The

mechanism by which the neurotoxic effect of the amphetamine
analogs occurs has been the subject of research for many

years.

Although several mechanisms have been proposed to

explain dopamine-mediated neurotoxicity of amphetamines,
current research supports the role of free radicals.

In

this model, it is proposed that amphetamine displaces

dopamine from synaptic vesicles to the cytoplasm, allowing
intraneuronal oxidative stress (Wan et al., 2000).

This

occurs because amphetamines cause an increase in dopamine
levels that result in a higher rate of dopamine metabolism.

Dopamine metabolism produces free radicals which are
chemical species that contain unpaired electrons.

They are

highly reactive and can cause damage' to nucleic acids,
lipids, and proteins.

Once a free radical is formed, it

can react with dopamine to form 6-OHDA, a toxic hydroxy
radical.

It is postulated that with large amounts of

dopamine in the synaptic cleft after methamphetamine

treatment, a small proportion of dopamine could be
metabolized to 6-OHDA and transported back into the
dopamine neuron through the dopamine transporter (Seiden &
Sabol, 1996).

This model suggests that the formation of

toxic hydroxy radicals from dopamine is the specific
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mechanism by which, amphetamines exert their neurotoxic
effect.
Evidence for the role of free radicals in the

neurotoxicity of amphetamines comes from research showing

that administration of antioxidants such as ascorbic acid
or vitamin E attenuates methamphetamine-induced

neurotoxicity (DeVito & Wagner, 1989; Wagner et al., 1985),
whereas inhibition of the antioxidant, superoxide dismutase

(SOD), by diethyl-dithiocarbamate increases neurotoxicity

(DeVito & Wagner, 1989).

Research has shown that there is

a production of superoxide radicals in the striatum of mice
treated with methamphetamine (Cadet, Ladenheim, Baum,

Carlson, and Epstien, 1994; Hirata, Ladenheim, Carlson,
Epstein, and Cadet, 1996).

This increase in superoxide

radicals is caused by the release of dopamine after

methamphetamine administration and subsequent dopamine
oxidation within dopamine terminals (Baldwin et al., 1993;

Marshall et al., 1993).

Studies such as these have led to

the theory that toxicity of methamphetamine and associated
increase in dopamine oxidation is the result of free

radical formation.
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Dopamine Is Essential for
Neurotoxicity

Evidence has shown that dopamine is essential for
methamphetamine-induced neurotoxicity (Gibb & Kogan, 1979;
Schmidt, Ritter, Sonsalla, Hanson & Gibb, 1985). When aMPT,

which blocks dopamine synthesis, is administered
concurrently with methamphetamine, it prevents
methamphetamine-induced decreases in tyrosine hydroxylase
activity and on concentrations of dopamine and its

metabolites (Gibb, Johnson & Hanson, -1990) .

When dopamine

synthesis was reinstated by concurrent administration of L-

DOPA, a precursor to dopamine, neurotoxicity was again
observed (Gibb & Kogan, 1979).

Additional evidence supporting the role of dopamine in
methamphetamine-induced neurotoxicity comes from research
with dopamine antagonists such as haloperidol and

chlorpromazine.

The effect of methamphetamine on both

tyrosine hydroxylase and on concentrations of dopamine and
its metabolites were completely blocked by administration

of chlorpromazine (Buening & Gibb, 1974).

These results

provide evidence that dopamine mediates methamphetamineinduced neurotoxicity.
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Conclusion
Research has shown that amphetamines produce longlasting neurochemical and morphological alterations to the

dopaminergic system.

Because of this, amphetamines are

considered neurotoxic to dopamine nerve cells.
Specifically, amphetamines have been found to exert their

neurotoxic effect by reducing striatal tyrosine hydroxylase
activity, depleting striatal dopamine and its metabolites,

decreasing number of dopamine uptake sites, and resulting
in dopamine nerve terminal degeneration.

The dopaminergic

system has been implicated in several important functions,
including movement, attention, learning, and the

reinforcing effects of drugs of abuse (Carlson, 2001) .

Therefore, the neurotoxic effects produced by amphetamines
may disrupt the overall functioning of the dopaminergic
system.

One particular area of interest is whether

amphetamines alter brain neurochemistry to the extent that

drugs of abuse become more rewarding.

Furthermore, the

question remains whether amphetamine-induced neurotoxicity

increases vulnerability towards drugs of abuse.
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CHAPTER THREE
DEVELOPMENTAL DIFFERENCES IN
AMPHETAMINE NEUROTOXICITY

Resistance to
Methamphetamine
Neurotoxicity in
Young Rats

Methamphetamine administration in adult rats results
in neurotoxicity characterized by reductions of neostriatal

dopamine, tyrosine hydroxylase, and dopamine transporter
sites (Bowyer et al., 1993).

In addition to effects on the

dopamine system, methamphetamine administration induces

increases in striatal glial fibrillary acidic protein
(GFAP) in adults (Pu & Vorhees, 1993).

.While adult rats

exhibit a characteristic pattern of long-term neurotoxic
effects when administered methamphetamine, developing rats

appear to be resistant to methamphetamine-induced

neurotoxicity (Cappon et al., 1997).

Methamphetamine

administered on PND .7-10 or PND 17-20 results in dopamine

reductions only about half as large as those seen in adults
(Lucot, Wagner, Schuster & Lewis, 1982).

In addition, it

has been found that there is a transition in susceptibility

to methamphetamine-induced neurotoxicity that occurs around
PND 40 in the rat (Pu & Vorhees, 1993).
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When examined 3

days following methamphetamine administration, PND 20 and
PND 40 rats failed to demonstrate decreased tyrosine
hydroxylase immunoreactivity.

However, in rats dosed at

PND 60, the normal adult pattern of decreased tyrosine
hydroxylase immunoreactivity was observed.

In addition, no

increase in GFAP was found in methamphetamine-treated PND

20 rats, but a small increase was seen at 40 days.
However, a large, adult-typical increase in GFAP was seen
after day 60 of treatment.

In another study, the acute and

persistent monoaminergic responses of adolescent (PND 40)

and young adults (PND 90) rats to multiple high doses of
methamphetamine was compared (Kokoshka, Flickenstein,

Wilkins & Hanson, 2000).

Results showed that

methamphetamine treatment significantly reduced dopamine
transporter activity, tyrosine hydroxylase activity, and
dopamine transporter ligand binding in the striatum of PND

90, but not PND 40 animals, to 33-53% of control values 7
days after treatment.

These findings confirm previous

findings that adolescent rats (PND 40) do not manifest

long-term deficits in dopamine systems after exposure to
methamphetamine treatment.

From these studies, it is

evident that there are age-dependent differences in the
impact of methamphetamine on the dopamine system.
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Hyperthermia in
Methamphetamine
Neurotoxicity
The severity of methamphetamine-induced neurotoxicity has

been found to correlate with an accompanying
thermoregulatory response, i.e., a hyperthermic response

facilitates neurotoxicity while a hypothermic response is
neuroprotective (Cappon et al., 1997).

Depletion of

striatal dopamine following methamphetamine administration

is linked to a hyperthermic response (Bowyer et al, 1994).
Specifically, decreases in striatal dopamine levels depend.
on the degree of hyperthermia produced during
methamphetamine exposure.

In addition, several agents that

block dopamine depletions do so by inhibiting

methamphetamine-induced hyperthermia.

Haloperidol,

diazepam, and dizoclipine (MK-801) all reduced

methamphetamine-induced striatal dopamine depletion to a
degree predicted by their inhibition of hyperthermia.
Also, cold environments that blocked methamphetamineinduced hyperthermia also blocked methamphetamine

neurotoxicity.

In addition, when marked hyperthermia was

produced, it was shown that methamphetamine increased the

number of astrocytes that contained GFAP immunoreactivity
and silver-degeneration staining in axons and terminals in
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the striatum.

From this study/ it can be concluded that

body temperature is a critical determinant of
methamphetamine neurotoxicity.

Hyperthermia in Resistance
to Methamphetamine
Neurotoxicity
in Young Rats
A thermoregulatory response has been proposed as a
contributing factor in the resistance to methamphetamine

neurotoxicity in developing rats.

The thermoregulatory and

neurotoxic effects of methamphetamine administration in
developing rats at PND 20, PND 40 and PND 60 were

investigated (Cappon, Morford & Vorhees, 1997).

Rats at

PND 20 and PND 40 were administered methamphetamine at

ambient temperatures of 22° C and 30° C, and PND 60 rats .
were administered methamphetamine at 22°C only.

Temperatures were measured and thermal responses were

compared by calculating the total thermal response (TTR)
induced by methamphetamine treatment.

Results showed that

methamphetamine administration to PND 60 rats at 22°C

induced a hyperthermic response, resulted in a 47%

reduction in neostriatal dopamine and a 49% increase in
GFAP content.

Administration of methamphetamine to PND 40

rats at 22°C failed to induce a hyperthermic response and
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did not result in reduced dopamine or increased GFAP.

However, administration of methamphetamine to PND 40 rats
at 30°C induced hyperthermia, reduced neostriatal dopamine
by 54% and increased GFAP by 70%.

Methamphetamine

administration to PND 20 rats at either 22° or 30° C did

not result in dopamine depletion or increased GFAP, even
though methamphetamine administration to PND 20 rats at

30°C induced hyperthermia.

This study provides evidence

confirming that the transition in neostriatal

susceptibility to methamphetamine occurs at approximately

40 days of age.

By contrast, the adult pattern is fully

developed by PND 60.

In addition, 20-day-old rats are

resistant to dopaminergic and GFAP effects induced by

methamphetamine treatment.
These findings illustrate the pivotal role of

methamphetamine-induced hyperthermia in the ontogeny of

methamphetamine-induced neurotoxicity (Cappon et al.,
1997).

Methamphetamine administered to PND 40 rats at 22°C

failed to induce hyperthermia and did not result in

dopamine depletion or reactive gliosis.

This suggests that

PND 40 rats are resistant to methamphetamine-induced

neurotoxicity.

However, PND 40 rats treated with

methamphetamine at an ambient temperature of 30°C
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demonstrate hyperthermia, dopamine depletion, and increased
GFAP.

Hence, at this age, resistance to methamphetamine-

induced neurotoxicity may be overcome by elevating ambient
temperature to produce hyperthermia.

This implies that the

neuroanatomical and/or neurochemical mechanisms underlying

methamphetamine-induced neurotoxicity have developed by PND
40, but the components necessary for methamphetamine to
induce hyperthermia are not yet fully mature.

Another

possibility is that PND 40 rats are able to dissipate
excessive heat into the environment better than adults.
PND 20 rats administered methamphetamine at 30°C

demonstrate a hyperthermic response comparable to that seen
in PND 40 animals, yet they are resistant to

methamphetamine-induced reactive gliosis and dopamine
depletions.

Consequently, PND 20 rats, unlike PND 40 rats,

are resistant to methamphetamine-induced neurotoxicity
despite induction of hyperthermia.

This indicates that the

neuroanatomical and/or neurochemical mechanisms responsible
for methamphetamine-induced neurotoxicity are not present

at PND 20.

From this, it can be concluded that

susceptibility to methamphetamine-induced neurotoxicity is

dependent upon the developmental stage in which it is
administered.

34

CHAPTER FOUR
ANIMAL MODELS OF DRUG
REWARD

Introduction

Addiction and drug abuse are significant problems in
the world today.

Research on drug abuse and addiction

takes place at many different levels.

Within the field of

neuropsychopharmacology, examination of the neurai

mechanisms of drug reward has become a major area of

research.

There are two measures that are most, frequently

used within a laboratory setting to assess the rewarding
properties of drugs., conditioned place preference (CPP) and
drug self-administration.

With few exceptions, drugs that

are self-administered have also been found to reliably

produce CPP, and vice versa (Carr, Fibiger & Philips,
1989) .
However, since the e_arly 1980's, there has been some

disagreement about whether CPP and self-administration
represent two alternative methods for measuring a common

reward process (Bardo & Bevins, 2000).

The controversy has

been fueled partly by different views regarding the nature

of reward. Reward has sometimes been equated with the
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subjective experience of pleasure, but science requires

that the concept of reward be related to the organizing
effects that it has on behavior (White, Messier & Carr,
1987).

Two major organizing effects of reward have been

identified (Carr et al., 1989).

The most prominent effect

is that stimuli which are generally agreed to be rewarding

(incentive stimuli) have the capacity to elicit approach
responses and maintenance of contact with stimuli
(Schneirla, 1959). Another organizing effect of reward is

its capacity to increase the probability that responses
that precede it will be repeated.

This strengthening of

the association between environmental stimuli and preceding
response has resulted in this effect being referred to as

'reinforcement'

(Skinner, 1938).

Reward Versus Reinforcement

As noted in the behavioral sciences literature, it is
important to remember that reinforcement and reward are two
distinct concepts (White, 1989).

Reinforcement is the

process that occurs in the nervous system when contact with
certain stimulus events (called reinforcers) produces a

change in behavior (White et al., 1987).

Skinner (1938)

defined a reinforcer as an event that follows a response
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and changes the probability that the response will be

emitted in the future.

A stimulus-response association may

be strengthened by reinforcement, but this strengthening
effect does not require that the reinforcer be rewarding or

pleasurable.

In fact, a reinforcer has the potential to be

aversive or punishing.

In a given environment, the

presence of reinforcing stimuli serves to organize behavior

by orienting the organism towards or against the stimulus
object (Young, 1966).

Therefore, reinforcement has come to

refer to the tendency of certain stimuli to strengthen
learned stimulus-response associations (White, 1989).
The notion of reward-has its origin in the writings of
philosophers, who described reward as individuals' natural

tendency to maximize pleasure and minimize pain.

This idea

has not changed in any substantial way since it was first

formulated.

In modern psychology, the operationalization

of affective states (e.g. reward and aversion), by Young

(1959), provided the model used now for studying these
behavioral processes.

According to Young's view, the

operational definition of reward is approach; the
operational definition of aversion is withdrawal.

In the

behavioral sciences, reward refers to the fact that certain
environmental stimuli have the property of eliciting
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approach responses and maintenance of contact.

The most

common contemporary measures of reward are electrical self
stimulation or self-administration of drugs, and various

place preference techniques.

Self-Administration
Paradigm
The self-administration paradigm is a valid and direct

measure of the reinforcing properties of the drug (Koob &
Goeders, 1989).

The drug self-administration technique

first requires a surgical procedure whereby a catheter is

inserted into the jugular vein of the animal.
for the intravenous infusion of drug.

This allows

The animal is then

placed in an operant chamber for self-administration

training and testing.

The operant chamber is an enclosed

environment with a small lever on the inside wall.

A lever

press will result in an intravenous injection of a drug.

A

signal light mounted above the lever can be used to
indicate the onset of injection and remains lit for a

period of time, during which the lever press will no longer

result in drug infusion.

Lever-pressing is reinforced

under a schedule of reinforcement (Koob & Goeders, 1989).

Training usually takes place under a fixed ratio (FR1)
schedule of reinforcement.

Under a FR1 schedule, every
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lever press results in a drug infusion.

Once regular

lever-pressing has been established, the schedule of

reinforcement can be increased.

Through the process of

operant conditioning, the animal will learn that drug

infusion is contingent upon pressing the lever.

The drug

is considered to be reinforcing if it increases the
probability of the lever-pressing response (Koob & Goeders,

1989).

The experimental analysis of biological and

environmental variables which modify the reinforcing
efficacy of the drug, i.e.,, the extent to which a drug is
self-administered, has implications for research on
problems of human drug-seeking behavior, addiction, and
dependence (Koob & Goeders, 1989) .

Conditioned Place
Preference Paradigm

CPP has been developed as an animal model of drug

reward.

To demonstrate CPP, animals are given a drug in

association with distinct environmental cues.

A typical

CPP experiment includes differentially pairing two distinct

sets of environmental (contextual) cues with the drug

stimulus.

The contextual cues tend to differ along several

stimulus dimensions.

The contexts may vary in flooring,

size or shape, wall color or pattern, and olfactory cues.
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Conditioning involves an animal receiving repeated exposure

to the drug stimulus (termed unconditioned stimulus or US)

in one context (termed conditioned stimulus or CS).
Intermixed with these context-drug pairings is similar
exposure to the other context without exposure to the drug

US (Bardo & Bevins, 2000).

Following conditioning is a

choice test in which animals receive unrestricted access to
both contexts in the absence of drug (US).

Therefore,

during testing, the animal is in a drug-free state.

An

increase in time spent in the paired context relative to
time spent in the paired context prior to conditioning is

taken as evidence that the drug (US) is rewarding (Bardo &
Bevins, 2000).

Presumably, after receiving pairings of a

drug with a particular environment, an animal that is now

drug-free will spend more time in the drug-paired
environment than in the neutral environment.

The increase

in time is attributed to the conditioned reinforcing
properties of environmental stimuli that have previously

been paired with drug (Hoffman, 1989) .

The drug is said to

be rewarding because the animal has shown a preference for
the environment paired with drug as opposed to the neutral

environment.
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What Is Learned in
Conditioned Place
Preference?
CPP is based on principles and operations of classical
The CPP paradigm is based on the

(Pavlovian) conditioning.

assumption that animals will approach rewarding stimuli and

that neutral stimuli can acquire secondary rewarding
properties through association with primary rewards (Carr
et al., 1989).

The primary rewarding properties of the

drug serve as an unconditioned stimulus'that is repeatedly

paired with a, previously neutral set of environmental

stimuli.

The neutral set of environmental stimuli acquire,

in the course of conditioning, secondary rewarding
properties.

Having acquired secondary rewarding

properties, they can act as conditioned stimuli which
elicit approach when the animal is subsequently exposed to

these stimuli in the absence of drug (Tzschentke, 1998).

Several lines of evidence support the assumption that
CPP involves the acquisition of a reinforcing conditioned
response (CR) in which reinforcing properties of the drug
become associated with environmental stimuli (Bardo, Miller

& Neisewander, 1984).

First, it has been shown that

various drugs may serve as effective primary reinforcers

(Grabowski & Cherek, 1983).
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Second, environmental stimuli

which are paired reliably with a drug may elicit a
conditioned response that mimics unconditioned drug

effects.

For example, a low dose of morphine produces

hyperthermia, and stimuli associated with this drug effect

can elicit a similar hyperthermic conditioned response
(Miksic, Smith, Numan & Lal, 1975).

Third, evidence

indicates that environmental stimuli associated with a
reinforcing drug can direct operant behavior.

For example,

rats injected with morphine in association with an
environmental stimulus will perform an operant response
which delivers the environmental stimulus alone (Schuster &

Woods, 1968) .

In CPP, the conditioned response (CR) is not observed

directly, but rather is assumed to be reflected in the
increased time that an animal spends in the presence of
drug-associated stimuli (Bardo et al., 1984).

This

assumption is substantiated by research showing that, the

CPP paradigm demonstrates other principles of Pavlovian
conditioning.

In Pavlovian conditioning, extinction is a

technique for producing a reduction and eventual

disappearance of the conditioned response (Klein, 2002).
Extinction involves repeatedly presenting the conditioned

stimulus without the unconditioned stimulus (Mazur, 1999).
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The strength of the conditioned response decreases as the
number of CS-alone experiences increases until, eventually,

the conditioned stimulus (CS) elicits no conditioned
response (CR)

(Klein, 2002).

Research has successfully

demonstrated that the CPP response (CR) can be extinguished
when drug-associated stimuli are presented alone following
conditioning (Mueller, Perdikaris & Stewart, 2002; Mueller

& Stewart, 2000).

Another principle of Pavlovian conditioning that has
been successfully demonstrated using the CPP paradigm is
reinstatement. Reinstatement involves the ability of
conditioned stimuli (CS) to once again elicit a conditioned

response (CR) following extinction.

Once a CPP (CR) has

been extinguished, it can be reinstated following a priming

injection of the drug (US)
Luo, Zhang & Han, 2000).

(Parker, & McDonald, 2000; Wang,
The extinction / reinstatement

paradigm is often used as a model of relapse to drug use
(Fuchs, Tran-Nguyen, Specio, Groff & Neiswander, 1998).

Comparison Between
Self-Administration and
Conditioned Place
Preference
There are three major advantages of drug self

administration.

First, self-administration of a drug by an
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animal is a direct measure of the reinforcing properties of
the drug.

The drug increases the probability of a response

and thus acts as a reinforcer.

This construct therefore

enables the use of classical operant techniques for the
measurement of motivational values of a drug, allows for

the measure of relative reinforcement value of drugs, and
controls for non-specificity of action of drugs and

assessment of treatment effects (Koob & Goeders, 1989).
Another advantage of drug self-administration is that

clear dose-effect functions can be obtained even in
continuous reinforcement situations, and these dose-effect

functions lend themselves to pharmacological antagonism.
An antagonism results in a shift of the dose-effect

function to the right, which at certain doses, is reflected

in an actual increase in responding for drug.

Injection of

an antagonist would produce an increase in the number of
self-injections of drug.

This increase is generally

considered to reflect a competitive functional interaction.

The rat presumably increases drug self-administration to

compensate for the decreased effectiveness of the drug as a
reinforcer in the presence of partial receptor occupancy by
the antagonist.

Consequently, an increase in self

administration resulting from administration of a drug
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antagonist is qualitatively similar to the effects of
decreasing the dose of drug per injection (Koob & Goeders,

1989).
The third advantage of self-administration for the

study of drug reinforcement is that this procedure can be
used to study the biological site of action of drugs.
Systemic and local intracerebral injections of

pharmacological antagonists and neurochemically specific
neurotoxins can be combined with these behavioral
procedures to define site and mechanism of action for the
reinforcing properties of drugs (Koob & Goeders, 1989).

There are three main disadvantages of drug self
administration as measures of the reinforcing properties of
drugs.

First, surgery is required that can be difficult in

small rodents.

Several particular precautionary procedures

must be used to prevent contamination, and reduce the

problems associated with blood clots and infection (Koob &
Goeders, 198 9).

Secondly, the lever-press response has to be learned,
and time is required for animals to reach stable baselines.
For heroin and cocaine, a 7-to-14-day period is required

for animals to stabilize lever-pressing response (Koob &
Goeders, 1989) .
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The final disadvantage centers on the general non
specificity of action of drugs.

Drugs, rarely, if ever,

have one specific neuropharmacological action, and in the

intravenous technique, drug is delivered throughout the
brain and body.

This limits the interpretation of some of

the behavioral preparations, particularly if 'nonreinforcing' actions are interfering with the ability of

the animal to respond.

Intracranial self-administration is

one procedure that can be used to circumvent many of the

non-specific effects associated with systemic drug delivery
(Koob & Goeders, 1989) .
The main advantages of CPP as an animal model of drug
reward are (1) the CPP paradigm allows for either a

preference (CPP) or an aversion (CPA) to be observed after
drug conditioning.

Thus, a major benefit in using this

technique is that both rewarding as well as aversive
properties of a drug can be determined using the same

behavioral task;

(2) time spent in the environment can be

measured in an animal that is drug-free.

Thus, any other

effects of the drug that may coexist with its
rewarding/aversive properties would not directly influence

the time spent in the previously drug-paired environment.
In contrast, using a self-administration paradigm, the
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lever-pressing response is measured while the animal is
under the influence of the drug.

Therefore, the

possibility exists that the lever pressing response may be

confounded by the stimulating or sedating effects of the
drug;

(3) the CPP preference has been observed with

relatively low doses of drug as compared to self

administration;

(4) the possibility exists that CPP can be

demonstrated in as little as one drug pairing, and when

multiple pairings are used, these pairings can be conducted

either once or twice daily without a decrement in the

associative strength of conditioning.

Thus, the relatively

short time necessary for this procedure (i.e., it only

requires 1 or 2 weeks) is an advantage.

This contrasts

with self-administration in which repeated self-infusions

of drug are required in order to establish reliable lever

pressing behavior.

This repeated exposure protocol likely

affects receptor transduction mechanisms related to

tolerance and/or sensitization (Bardo & Bevins, 2000);

(5)

CPP allows for simultaneous assessment of place preference

and locomotor activity;

(6) CPP typically yields dose

effect curves that are monophasic.

This contrasts with

self-administration which typically yields a biphasic dose

effect curve;

(7) Drugs that have been shown to produce CPP
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are consistently shown to be rewarding/reinforcing in other

behavioral paradigms.

Drugs of abuse are able to produce

CPP and possess reinforcing properties in operant
behavioral tasks (Carr et al., 1989).

Thus, predictions

from the CPP task as to the rewarding properties of drugs

are consistent with predictions from other behavioral

paradigms (Schechter & Calcagnetti, 1993).

Despite its numerous advantages, there are some

limitations of CPP as a measure of drug reward.

(1) There

are some questions regarding what exactly is being measured

by the CPP paradigm (Schecter & Calcagnetti, 1993).

The

possibility exists that animals are not really expressing a
drug-environmental paired preference, but rather are simply
being affected by locomotor activating / sedating actions

of the drug.

(2) A major concern regarding CPP is the

potential confounding influence of novelty-seeking behavior
on test day.

It is well established that rats prefer a

novel context over a familiar context (Hughes, 1968).

This

finding leads to the possibility that pairing drug with one
context retards or blocks complete familiarization to that

context, thus rendering it more novel relative to the
saline context on the drug-free test day (Bardo & Bevins,

2000).

One way that researchers have dealt with the issue
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of novelty is to test animals in an apparatus that has

three distinct contexts - one that is novel, one that is
drug-paired, and one that is saline-paired.

When tested in

this situation, rats show a preference for the drug-paired

context relative to the novel context (Parker, 1992).

(3)

Deficits in performance produced by drug-state dependency
may be considered another limitation of CPP.

Animals are

trained in one state in that they experience the drug
effect in a particular environment and they are later

tested in a different state (drug-free).

The possibility

exists that the inability to express a preference for the

drug-paired environment is inherent in the fact that
training and testing occur in different subjective states
(Schechter & Calcagnetti, 1993).

(4) A final limitation of

CPP is the difficulty in generating the type of dose-effect

relationship normally expected in behavioral pharmacology
(Bardo & Bevins, 2000).

In many cases, does-response

relationships have not been observed by varying the dose of

drugs used successfully to produce a CPP.

What is often

observed is a "step-up" dose-effect relationship where one

dose does not produce CPP but the next higher dose produces
a positive and maximal effect (Schechter & Calcagnetti,
1993) .
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Are Conditioned Place
Preference and
Self-Administration
Comparable Methods for
Measuring Drug Reward?
There has been conflicting data as to whether CPP and

drug self-administration measure a common reward process.

Partial support for the claim that CPP is similar to self
administration arises when one compares the ability of each
paradigm to detect reward across various drug classes.

There appears to be reasonable concordance between drugs
that produce CPP and drugs that are self-administered.

Various stimulants, opiates and other drugs are known to
support both CPP and self-administration (Bardo & Bevins,
2000).

In contrast, neither CPP nor self-administration is

produced by a host of other drug classes, including
antagonists for dopamine, opioid, and cholinergic
receptors, as well as antidepressants that work on either

noradrenergic or serotonergic systems (Bardo & Bevins,

2000) .

Despite this commonality, there are some significant
exceptions to the general concordance between CPP and self
administration across drug classes.

CPP may be unique in

its ability to detect the rewarding effect of lysergic acid

diethylamide (Meehan & Schecter, 1998), buspirone (Balster,
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1990) , and pentylenetetrazole (Gauvin, Dormer & Holloway,
1991) , whereas self-administration may be unique in its

ability to detect the rewarding effects of pentobarbital
(Collins, Weeks, Cooper, Good & Russell, 1984) and

phencylclidine (Marquis, Webb & Moreton, 1989).

This

discordance indicates that CPP and self-administration are

not similar measures of a common reward process (Bardo &

Bevins, 2000) .
In addition to the discrepancy between CPP and self

administration noted across some drug types, several recent
studies have demonstrated a clear dissociation between CPP

and self-administration.

In one study, rats were allowed

to self-administer cocaine for either 6 or 29 sessions.
These two groups were then examined for cocaine CPP, as

well as reinstatement of self-administration using a

cocaine cue (Deroche, Le Moal & Piazza, 1999).

Although

the 29-session group self-administered more cocaine than

the 6-session group and showed greater sensitivity to

cocaine's ability to reinstate operant responding, no group
differences in the dose response curve for cocaine CPP were

obtained.

These results provide strong evidence that CPP

and self-administration are measuring fundamentally
different processes.
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There are also several examples which indicate that

the neuropharmacological mechanisms that underlie CPP and

self-administration are dissociable.

One illustration of

this point comes from studies examining the effects of D2

dopamine antagonists on cocaine CPP and self-administration
in rats.

In general, studies have shown that systemic

administration of cocaine induces a CPP that is not altered

by pretreatment injections of various D2 antagonists

administered either systemically (Cervo & Samanin, 1995) or
directly into the nucleus accumbens (Baker, Khroyan,

O'Dell, Fuchs & Neisewander, 1996).

This outcome

contrasts with self-administration studies demonstrating
that the reinforcing effect of cocaine is attenuated by D2

antagonists administered either systemically (Ettenberg,
Pettit, Bloom & Koob, 1982) or into the nucleus accumbens

(Phillips, Howes, Whitelaw, Robbins & Everitt, 1994).
Thus, D2 dopamine receptors appear to be involved in the
primary reinforcing effect of cocaine, but not in the

rewarding effect of contextual stimuli paired with cocaine

(Bardo & Bevins, 2000) .
In conclusion, it is apparent that there is
conflicting evidence as to whether CPP and self

administration are similar measures of drug reward.
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However, the emphasis should not be placed on demonstrating
CPP and self-administration as measures of a common reward
process.

Numerous studies have shown both paradigms to be

valid measures of drug reward.

CPP and self-administration

uniquely contribute to our understanding of the neural
mechanism underlying drug reward.

Further research

utilizing these two animal models of drug reward will

ultimately add to our understanding of drug addiction and

abuse liability.
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CHAPTER FIVE
THE DOPAMINE SYSTEM

AND REWARD

Introduction

The dopaminergic system has been profoundly implicated
in reward mechanisms.

It is generally acknowledged that

dopamine receptors in the mesolimbic system mediate the

motivational-affective role of dopamine, while dopamine in
the striatum is responsible for facilitating complex motor
responses (Ikemoto & Panksepp, 1999) .

The mesolimbic

system includes the dopamine pathway projecting from the

ventral tegmental area (VTA) to the nucleus accumbens

(Carlson, 2001) .

The nucleus accumbens is often cited as a

structure linked with the reward role of dopamine (Stellar,
Keley & Corbett, 1983).

The nucleus accumbens can be

divided into two major sub-regions: the shell (ventromedial
part) and the core (dorsolateral part)

(Ikemoto & Panksepp,

1999).
Self-Administration Studies
The most convincing evidence that supports the role

of the mesolimbic dopamine system in reward is that animals

self-administer chemicals that mimic dopamine (i.e. direct
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dopamine receptor agonists) or increase extracellular

dopamine (i.e. indirect agonists, e.g., amphetamine)
directly into the nucleus accumbens.

In operant

procedures, the response contingent delivery of dopamine
agonists directly into the nucleus accumbens can serve as a

reinforcer for that response (i.e. increase its future

probability of occurrence or strength of association)

(Ikemoto & Panksepp, 1999).

Rats self-administer d-

amphetamine within the nucleus accumbens more so than equal

amounts of saline (Hoebel, Monaco, Hernandez, Aulisi,
Stanley & Lenard, 1983).

In addition, rats will self-

administer nomifensine, a dopamine reuptake blocker, into
the nucleus accumbens (Carlezon, Devine & Wise, 1995).

These results suggest that response-contingent dopamine
reuptake blockade within the nucleus accumbens is
sufficient to establish and maintain instrumental response

habits.

Furthermore, rats acquire and maintain self

administration of direct dopamine' receptor agonists, a
mixture of SKF 38393 (a Dl-like agonist) and quinpirole (a

D2-like agonist), into the nucleus accumbens (Ikemoto,
Glazier, Murphy & McBride, 1997).
Additional support for the role of dopamine in reward

comes from research on substance abuse.
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Mammalian species

readily acquire and maintain self-administration of
psychostimulants such as amphetamine and cocaine (Schuster
& Thompson, 1969).

Amphetamine and cocaine are known to

stimulate dopamine release and block reuptake in the
nucleus accumbens.

The mesoaccumbens dopamine system

appears to play a critical role in mediating reinforcing
effects of these psychostimulants.

The role of dopamine in

the reinforcing properties of psychostimulants can best be
exemplified by studies showing that pharmacological
manipulation of the dopamine system can affect self

administration of these drugs.

In one study, dopamine

nerve terminals in the nucleus accumbens were destroyed

with 6-OHDA (Lyness, Friedle & Moore, 1979).

It was found

that 6-OHDA injections into the nucleus accumbens abolished
the acquisition of d-amphetamine self-administration.

The

results suggest that dopamine neurons in the nucleus
accumbens subserve the activation of a reward system.

Removal of dopaminergic nerve terminals would result in a
failure of indirect agonists like d-amphetamine to produce

a positive (rewarding) stimulus.

Therefore, one would

expect poor acquisition of'self-administration behavior.
Additionally, in an effort to define the neural circuitry
involved in the reinforcing effects of cocaine, the effect
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of 6-OHDA-induced lesions of specific catecholamine

pathways and terminal areas on cocaine self-administration

was examined (Roberts, Koob, Klonoff & Fibiger, 1979).
After cocaine self-administration behavior had stabilized,

the nucleus accumbens was injected with 6-OHDA.

When

tested the day following the 6-OHDA injection, rats failed
to self-administer cocaine.
not resemble extinction.

However, this disruption did

After several days, self

administration recovered in many animals to near
preoperative levels.

The rate of this recovery correlated

with levels of dopamine remaining in the nucleus accumbens.
The animals with the greatest depletion of dopamine did not
recover cocaine intake.

The results therefore support the

hypothesis that cocaine interacts with dopaminergic

neuronal mechanisms to produce reinforcement and maintain
self-administration behavior.

Conditioned Place
Preference Studies
CPP has also been used to demonstrate the role of

dopamine in the rewarding effects of d-amphetamine and

direct dopamine agonists (Ikemoto & Panksepp, 1999).
Intra-accumbens injections of amphetamine result in a
strong CPP (Carr and White, 1986).
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The observation of a

CPP indicates that intra-accumbens injections were

rewarding.

Adding the dopamine receptor blocker cis-

flupenthixol to the injection fluid attenuates the CPP

produced by intra-accumbens amphetamine (Ausili & Hoebel,
1983).

In addition, systemic injected haloperidol, a

dopamine receptor antagonist, blocks amphetamine-induced
CPP (Phillips, Spyraki & Fibiger, 1982).

Dopaminergic

involvement is also implicated by the attenuation of

amphetamine. CPP using selective 6-OHDA lesions of accumbens

dopamine neurons (Spyraki et al., 1982).

These findings

suggest that dopamine release and receptor activation in
the nucleus accumbens are both necessary and sufficient to
produce CPP (White, Packard & Hiroi, 1991).

. ■Brain.Self-Stimulation
Studies

The brain-stimulation reward paradigm has played a
major role in initiating the idea of dopamine being a

central substrate of brain reward (Lippa, Antelman, Fisher
& Canfield, 1973).

Animals readily learn to lever-press

when the lever press results in a brief electrical
stimulation (Olds, 1958).

Electrical stimulation to the

medial forebrain bundle, a major pathway interconnecting
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the midbrain and forebrain, has been found to be stronglyrewarding (Colle & Wise, 1988).

Systematic manipulations of brain dopamine receptors
have marked effects on self-stimulation behavior.

The most

compelling evidence suggesting dopaminergic involvement

derives from pharmacological studies.

Dopamine agonists

and antagonists, respectively, facilitate and disrupt self
stimulation behavior (Ikemoto & Panksepp, 1999).

The

effect of pimozide, a specific blocker of dopamine

receptors, and amphetamine, a dopamine agonist, on self
stimulation of the medial forebrain bundle was examined

(Gallistel & Karras, 1983).

It was found that pimozide

decreased rate of self-stimulation behavior, thereby

decreasing the rewarding value of brain-stimulation.
Conversely, amphetamine increased rate of self-stimulation,
thereby increasing the rewarding value of brain-

stimulation.

Finally, the effect of concurrent

administration of pimozide and amphetamine cancelled each

other out.

When administering the combination of pimozide

and amphetamine, rate of self-stimulation was intermediate
to the effects of the two individual treatments.

These

results support the hypothesis that pimozide and
amphetamine exert their effects on reward via the same set
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In addition, application of

of dopaminergic synapses.

brain stimulation in the VTA increases dopamine levels
within the nucleus accumbens (Blaha & Phillips, 1990).

This finding is consistent with the notion of a
dopaminergic substrate of brain stimulation reward at

electrode sites in the VTA.

Other Drugs of Abuse
Stimulate Dopamine Release

The potential importance for the role of dopamine in
the rewarding properties of drugs is further highlighted by
findings that many other drugs of abuse, including ethanol,

opioids, cannabis and nicotine, share the ability to
selectively stimulate dopamine release within the

mesolimbic system (Ikemoto & Panksepp, 1999).

Intra

parietal administration of ethanol stimulates dopamine
release and DOPAC and HVA output in the■nucleus accumbens,
and although less, also in the caudate (Imperato & Di

Chiara, 1986).

In addition, intravenous administration of

both heroin and delta-9-tetrahydrocannabinol, the active

ingredient in cannabis, increase extracellular dopamine
concentrations in the nucleus accumbens (Tanda, Pontieri &

Di Chiara, 1997).

Lastly, nicotine administration results

in an increase in dopamine transmission in the nucleus
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accumbens and caudate (Imperato., Mulas & Di Chiara, 1986) .

These findings suggest that the reinforcing properties of
these drugs may be mediated by its action on the mesolimbic

dopamine system.

Conclusion

In summary, there is a large body of evidence

supporting the involvement of dopamine in the rewarding
value of stimuli.

Behavioral studies such as self-

administration, CPP and electrical brain stimulation all

link dopamine to reward.

Also, studies examining drugs of

abuse have shown that dopamine mediates the rewarding

properties of drugs.

Additionally, studies have found

dopamine to play a role in the rewarding properties of

natural reinforcers such as food intake (Weingarten &
Watson, 1989), sucrose consumption (Muscat & Willner,

1989), water intake (Gilbert & Cooper, 1987), and
temperature reinforcement (Ettenberg & Carlisle, 1985).

These highly consistent lines of evidence affirm that
dopamine plays an important role in the reward system.
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CHAPTER SIX
, AMPHETAMINE IMPACTS, REWARD

Introduction

It is now well accepted that amphetamine
administration can be neurotoxic to dopamine neurons. A

possible consequence of this toxicity is an alteration to

neural reward centers as dopamine is known to be an
important mediator of rewarded behavior.

In addition,

researchers have compiled compelling evidence that has
implicated dopamine as a central substrate of reward

(Lippa, Antelman, Fisher & Canfield, 1973).

Since

amphetamines are neurotoxic to the dopamine system, and
being that dopamine plays an important role in reward, it
is probable that amphetamine would impact reward mechanisms

in the brain.

In an effort to investigate the impact of amphetamine
on reward, researchers have conducted studies where they

pre-treat animals with amphetamine and then assess
rewarding effects of drugs using behavioral measures such

as drug self-administration and CPP.

However, there have

been relatively few studies that have investigated the
impact of repeated amphetamine exposure on reward.
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Furthermore, the research that has examined the impact of
amphetamine exposure on reward has been controversial.

Some research indicates that amphetamines increase the

rewarding value of drugs of abuse while other studies

suggest that amphetamines decrease the rewarding value of
drugs of abuse.

Behavioral Research:
Evidence that Amphetamine
Impacts Reward

One study obtained results that support the theory

that prior exposure to amphetamine decreases the rewarding
value of drugs (Itzhak & Ali, 2002).

Specifically, this

study examined the consequences of methamphetamine-induced
neurotoxicity on methamphetamine place preference.

The

acquisition and reinstatement of methamphetamine-induced

CPP was measured in drug pretreated and saline pretreated
mice.

Saline pretreated mice showed a much stronger

preference for the methamphetamine-paired room as compared

to the methamphetamine pretreated mice. Moreover, it took

longer to extinguish the conditioned response of the saline
pretreated group in comparison to the methamphetamine

group.

In addition, the saline pretreated rats showed

stronger reinstatement of the place preference after a
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priming injection of methamphetamine.

The results of this

study suggest that pretreatment with a neurotoxic dose of
methamphetamine decreases the rewarding value of subsequent

methamphetamine exposure.

The results of this study

support the theory that amphetamines decrease the rewarding

value of drugs of abuse.
A similar study to that of Itzhak and Ali (2002) was

conducted, but obtained results that support the theory
that amphetamine pre-exposure increases the rewarding value

of drugs (Gehrke, Harrod, Cass & Bardo, 2003).

Rats were

pretreated with a neurotoxic regimen of methamphetamine or
saline, and were then conditioned 7 days later with
methamphetamine (0.1, 0.3, or 1.0 mg/kg, s.c.) or saline

using a CPP procedure.

Results indicated that a neurotoxic

dose of methamphetamine did alter subsequent
methamphetamine CPP.

For saline controls, only rats that

received 1.0 mg/kg methamphetamine during conditioning

demonstrated CPP.

In contrast, rats that received the

neurotoxic dose of methamphetamine demonstrated CPP when

administered either 0.3 or 1.0 mg/kg methamphetamine.
These results indicate that the rewarding effect of

methamphetamine was enhanced by neurotoxic doses of

methamphetamine.
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Another study lends further support to the theory that
amphetamines increase the rewarding value of drugs (Lett,

1989).

Animals were divided into groups and pretreated

with either d-amphetamine or morphine.

Animals were then

tested for either amphetamine-induced or morphine-induced
CPP.

Results showed that repeated exposure to amphetamine

or morphine enhanced the drug-induced rewarding effects
measured by CPP.

This study also showed that cross-drug

effects exist: exposure to amphetamine enhanced the
rewarding effect of morphine, and exposure to morphine

enhanced the rewarding effect of amphetamine.

This cross

drug effect is of particular importance because it suggests

that a common neural mechanism mediates the rewarding
effect of drugs with varying mechanisms of action.

The

study suggests that with repeated exposure to drugs, the
probability of addiction increases because drug-taking
produces a progressively greater reinforcing effect each
time it occurs (Lett, 1989).
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The Dopamine D2 Receptor
Hypothesis: The Role of
the Dopamine D2 Receptor
in the Ability of
Amphetamine to Impact
Reward
The neural mechanisms underlying the way in which

amphetamine impacts reward is not completely understood,

but it is hypothesized that dopamine D2 receptors play a key
Current research has shown that exposure to

role.

amphetamine reduces the number of dopamine D2 receptor

binding sites (Bennett, Hollingsworth, Martin & Harp, 1998;

Chen, Su, Huang & Hsieh, 1999; McCabe, Hanson, Dawson,
Wamsley & Gibb, 1987; Volkow et al., 2001).

Furthermore,

research has demonstrated that dopamine D2 receptor levels

are predictive of the rewarding properties of drugs of

abuse.

Studies have shown that lower levels of D2 receptors

are associated with increased drug-liking, pleasure, and

euphoria (Laruelle, Abi-Dargham, van Dyck, Rosenblatt, ZeaPonce & Zoghbi, 1995; Volkow, Wang, Fowler, Logan, Gatley,

Gifford et al. 1999).

Evidence that Amphetamine
Alters Dopamine D2
Receptors
In one study, methamphetamine-induced reductions of D2
receptors in several areas of the rat central nervous
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system were measured (McCabe, Hanson, Dawson, Wamsley &

Gibb, 1987).

Results showed a reduction in amount of

[3H]sulpiride binding sites in

doses of methamphetamine.

rat striatum after multiple

A significant reduction in

[3H]sulpiride binding was demonstrated in the striatum
(29.4%), nucleus accumbens (36.7%), and olfactory tubercle
(39.4%).

Analysis indicated that the methamphetamine-

induced reduction in [3H]sulpiride binding to D2 receptor

sites was due to changes in number of receptors rather than
affinity. These results suggest that receptor changes may

be attributed to amount of dopamine released;
methamphetamine releases amounts of dopamine that would
result in a down-regulation of dopamine receptors.

In

another study, the effect of methamphetamine exposure on
dopamine D2 receptor binding in cultured midbrain dopamine

neurons was examined (Bennett, Hollingsworth, Martin &

Harp, 1998) .

Pretreatment with methamphetamine was found

to decrease the Bmax for [3H] raclopride binding, suggesting
that methamphetamine causes a down-regulation of dopamine D2
receptors.

Additionally, following examination of D2

receptor binding in rat striatum treated with amphetamine,
it was found that the Bmax value of D2 receptors in the
striatum decreased 40% on day 7 and 52% on day 10 after
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amphetamine withdrawal, without changes in their binding

affinities (Kd)

(Chen, Su, Huang and Hsieh, 1999) .

The

findings demonstrate that amphetamine administration for a
period of 14 days leads to diminished D2 receptor binding in
the striatum at late withdrawal periods.

Research linking amphetamine to decreased dopamine D2
receptor sites was extended by measuring levels of dopamine

D2 receptors in human methamphetamine abusers (Volkow et
al., 2001).

Fifteen methamphetamine abusers and 20

nondrug-abusing comparison subjects were studied using

positron emission tomography (PET) to assess availability

of dopamine D2 receptors.

Results indicated that

methamphetamine abusers had a significantly lower level of

D2 receptor availability than comparison subjects (a
difference of 16% in the caudate and 10% in the putamen).

The results of these studies suggest that amphetamine,

in addition to causing changes in presynaptic dopamine

markers, also reduce postsynaptic dopamine D2 receptors.

It

was hypothesized that lower levels of D2 receptors in
amphetamine-treated subjects reflect receptor down

regulation from exposure to a higher extracellular dopamine
concentration (Chen et al., 1998).
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The down-regulation of

D2 receptors might reflect cellular mechanisms possibly
associated with amphetamine-induced neurotoxicity

Dopamine D2 Receptor Levels
Predict Reinforcing
Response to Drugs

Treatment with amphetamine results in a reduction in
number of dopamine D2 receptor binding sites.

This finding

is important, since studies have also demonstrated a
relationship between drug addiction and number of dopamine

D2 receptors (Laruelle et al., 1995; Volkow et al., 1999).

Specifically, these studies have found that number of
dopamine D2 receptors was predictive of the rewarding

properties of psychostimulants.

In one study, the relationship between the behavioral

effects of d-amphetamine and dopamine D2 receptor levels was
examined (Laruelle et al., 1995).

SPECT imaging was used

to measure dopamine D2 receptor levels.

Human subjects were

injected with d-amphetamine, and the behavioral effects of

the drug were measured by self-rating on the following
analog scales: euphoria, alertness, restlessness and
anxiety.

Results showed that d-amphetamine injection

induced a decrease in D2 receptor availability. The d-

amphetamine injection induced marked increase in euphoria,
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alertness and restlessness scores. The intensity of these

behavioral responses correlated with the decrease in D2

availability measured with SPECT. In contrast, the anxiety
response was milder and not correlated with decrease in D2

availability.
In another study, PET was used to determine if there
were differences in striatal dopamine D2 receptor levels

between those human subjects who reported the effects of
methylphenidate as pleasant and those who reported them as

unpleasant (Volkow et al., 1999).

The study also assessed

whether dopamine D2 receptor levels predict behavioral
responses to methylphenidate.

Results indicated that

subjects who liked the effects of methylphenidate had

significantly lower dopamine D2 receptor levels than
subjects who disliked its effects.

Moreover, the higher

the dopamine D2 levels found, the more intense were
methylphenidate's unpleasant effects.

The results of these studies provide evidence that
dopamine D2 receptor levels predict response to

psychostimulants in humans.

Additionally, these results

suggest that low levels of dopamine D2 receptors may

contribute to psychostimulant abuse by increasing
pleasurable effects of drugs.
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Studies using human subjects

support the same conclusions as those using animal
subjects: dopamine D2 receptor levels mediate reinforcing

responses to drugs of abuse.

However, while studies using

human subjects have shown- dopamine D2 receptor levels to

increase the reinforcing response to drugs, animal studies
have shown dopamine D2 receptor levels to decrease the

reinforcing response to drugs.

This is evidenced by the

decrease in the reinforcing effects of alcohol and morphine
in mice that lack dopamine D2 receptors (Maldonado, Saiardi,
Valverde, Samad, Roques & Borrelli, 1997; Phillips, Brown,

Burkhart-Kasch, Wenger, Kelly & Rubinstein, 1998), and by
the decrease in the reinforcing effects of cocaine in

animals given drugs to block dopamine D2 receptors (DeWit &
Wise, 1977; Spealman, 1990).

Conclusion

Research has demonstrated that amphetamines impact
reward.

While the neural mechanisms underlying the way in

which amphetamine impacts reward is not clearly understood,

it is hypothesized that the dopamine D2 receptor plays a

role in the ability of amphetamines to affect the reward
system.

Amphetamine administration reduces number of

dopamine D2. receptors. -Moreover, number of dopamine D2
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receptors is predictive of the rewarding properties of

psychostimulants.

Specifically, lower levels of dopamine D2

receptor sites are associated with increased drug reward.
However, research is needed to examine the role of D2

receptor in the ability of amphetamine to impact reward.

This research will expand our knowledge of the neurobiology

of drug addiction and,may help us understand why some

individuals are more predisposed to abuse drugs than
others.
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CHAPTER SEVEN
EARLY AMPHETAMINE EXPOSURE
AFFECTS REWARD AND LATER

BEHAVIOR

Early Amphetamine Exposure
Affects Reward
There are very few studies that have directly

investigated the impact of early amphetamine exposure on
reward.

The studies that have been done in this area have

been exclusive to methylphenidate.

This research has

looked at the effect of early methylphenidate exposure on
vulnerability towards drug abuse (Achat-Mendes, Anderson &

Itzhak, 2003; Anderson, Arvanitogiannis, Pliakas, LeBlanc &
Carlezon, 2001; Brandon, Marinelli, Baker & White, 2001).

Some studies suggest that early methylphenidate exposure
decreases later vulnerability towards drug abuse while

other studies suggest early methylphenidate exposure
increases later vulnerability toward drug abuse.
One study obtained results that support the theory

that early methylphenidate exposure decreases later
vulnerability towards drug abuse (Anderson et al., 2001).

In this study, rats were given intraperitoneal injections
of methylphenidate (2.0 mg/kg) or saline twice daily on PND
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20 to PND 35.

humans.

This period approximates pre-adolescence in

At PND 60, CPP was used to assess the rewarding

effects of cocaine.

Rats pretreated with saline during

development showed dose-related increases in the amount of
time spent in the environment associated with cocaine.

In

contrast, methylphenidate pretreated rats spent less time
in environments associated with a moderate dose of cocaine.

A higher dose of cocaine that established place preference
in saline pretreated rats failed to establish place
preferences in methylphenidate pretreated rats.

The

results of this study suggest methylphenidate exposure in

developing rats decreases responsiveness to the rewarding
effects of cocaine.

The findings suggest that early

exposure to methylphenidate makes drugs of abuse less
rewarding later in life.

In contrast, another study obtained results suggesting
that early methylphenidate exposure increases vulnerability
towards drug abuse (Brandon et al., 2001).

Adolescent rats

were pretreated with either methylphenidate (2 mg/kg for 7

days) or saline on PND 35 to PND 42.

In adulthood, the

reinforcing effects of cocaine were measured using drug

self-administration.

It was found that adolescent rats

pretreated with methylphenidate self-administered cocaine
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in adulthood at a higher rate compared to rats pretreated
with saline.

It was concluded that adolescent exposure to

low doses of methylphenidate may increase vulnerability to
the reinforcing effects of cocaine.

These findings support

the theory that early methylphenidate exposure increases
vulnerability towards drug abuse by increasing the

rewarding value of drugs.

In another study that looked at the effect of

adolescent methylphenidate exposure on drug reward,
adolescent mice received intraperitoneal injections of
methylphenidate (10 mg/kg) or saline on PND 26 to PND 32

(Achat-Mendes et al., 2003).

In adulthood, induction and

reinstatement of cocaine-induced CPP was assessed.

Methylphenidate pretreatment during adolescence resulted in

a reduced preference for the cocaine-paired compartment in
adulthood as compared to the saline pretreated animals.
However, 2 weeks following extinction of cocaine-induced

CPP and withdrawal from cocaine, a priming injection of
cocaine was given.

The priming injection of cocaine

reinstated significantly higher CPP in the methylphenidate

group than the saline group.

The findings suggest that

exposing mice to methylphenidate during adolescence

ultimately increases cocaine-induced reward in adulthood.
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This increased reward was observed particularly after a 2-

week withdrawal period from cocaine.

It is suggested that

exposure to methylphenidate in adolescence may cause
enduring neural adaptations that impact the reward system
in adulthood, causing a heightened propensity for drug
relapse (Achat-Mendes et al., 2003).

Methylphenidate may

trigger long-lasting neural adaptations that are expressed
as an increased sensitivity to a cocaine challenge

following withdrawal from cocaine.

This is believed to be

relevant to vulnerability to drug relapse (Achat-Mendes et
al., 2003).

Early Amphetamine Exposure
Affects Later Behavior

Although there are few studies that have directly
investigated the effect of early amphetamine exposure on

reward, there have been several studies that have examined
the effect of early amphetamine exposure on other
behavioral measures.

While developing rats appear to be

resistant to the neurotoxic effects of amphetamine,
behavioral deficits following amphetamine exposure have

been observed.

Rats pretreated with methamphetamine during

the preweanling period (PND 1-20) exhibit an augmented

acoustic startle response, reduced locomotor activity, and
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impaired performance in a complex multiple-T water maze
(Vorhees, Ahrens, Acuff-Smith, Schilling & Fisher, 1994).

Multiple-T mazes are considered to be tests of reference
memory and appear to involve processes such as vector

navigation using proximal cues (Etienne, 1992).

Therefore,

it appears that methamphetamine-pretreated preweanling rats
have long-term deficits in memory processes that depend on

stable cues and on determining spatial position based on
time and direction of movement (Vorhees et al., 1994).

In

addition, methamphetamine pretreatment during the

preweanling period results in adult learning deficits that
are specific to spatial navigation and memory (Vorhees,
Inman-Wood, Morford, Broening, Fukumara & Moran, 2000).

Furthermore, methamphetamine pretreatment during the

preweanling period induces selective impairment of
reference memory-based spatial learning while sparing

sequential cued, and working memory-based learning
(Williams, Morford, Wood, Wallace, Fukumura, Broening &
Vorhees, 2003).

Taken together, this research suggests

that the effects of methamphetamine exposure during the
preweanling period are both long-lasting and stage
dependent, impacting arousal as well as cognitive

functions.
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CHAPTER EIGHT
SUMMARY AND HYPOTHESIS

ADHD is the most common neuropsychiatric diagnosis in

children.

It is estimated that 3%-5% of children meet the

diagnostic criteria for ADHD (Palfrey, Levine, Walker &

Sullivan, 1985) .

Methylphenidate currently remains the

single most effective way to treat ADHD.

In addition, the

clinical use of methylphenidate for 3- to 6- year old

preschool children who meet the diagnostic criteria for

ADHD is becoming more common.

However, little is known

about long-term effects of methylphenidate on the very

young.

Given the increasing number of young children being

treated with methylphenidate, much more research is needed
to compare the safety and efficacy of stimulant medication
across development.

It is important to consider the

possibility of adverse effects of stimulant medication on

the developing brain.

One major concern is whether early

methylphenidate treatment would alter the brain in such a

way as to impact the rewarding■value of drugs, thereby
increasing later vulnerability towards drug abuse.

Amphetamines are known to be neurotoxic to the

dopamine system, and dopamine systems play a critical role
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in mediating the rewarding effects- of drugs.

Research has

shown that amphetamine exposure can impact drug reward.
However the results of this research have been
controversial, as some research indicates that amphetamine

exposure increases the rewarding value of drugs while other

studies suggest amphetamine exposure decreases the

rewarding value of drugs.

The neural mechanisms by which

amphetamines impact reward is not completely understood,

but it is hypothesized that the dopamine D2 receptor plays a
key role.

Repeated-exposure to. amphetamine reduces the

number of dopamine D2 receptor binding' sites (Bennett et
al., 1998; Chen et al., 1999; McCabe et al., 1987; Volkow
et. al., 2001).

Current research has demonstrated that

dopamine D2 receptor levels are predictive of the rewarding
properties of drugs (Volkow et al. 1999).

Studies have

shown that lower levels of D2 receptors are associated with
reports of increased drug-liking, pleasure, and euphoria
(Laruelle et al. 1995).

Since methylphenidate is an amphetamine, the question

remains as to whether repeated methylphenidate exposure,
like other amphetamines, decreases dopamine D2 receptor
levels and impacts drug reward.

It is possible that

methylphenidate treatment during development may decrease
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dopamine binding sites and thus increase later
vulnerability towards drug abuse.

A recent study found

that dopamine D2 receptor levels in the striatum declined as

a function of methylphenidate therapy in patients with ADHD
(Ilgin, Senol, Gucuyener, Gokcora, Atavci & Sener, 2001).

Research examining the effects of early
methylphenidate exposure on vulnerability towards drug

abuse is sparse, and the findings have been inconclusive.

Some studies suggest that early methylphenidate exposure
decreases later vulnerability towards drug abuse while

other studies suggest early methylphenidate exposure
increases later vulnerability toward drug abuse.

Furthermore, there has not been any research that has
examined the effect of methylphenidate exposure during the

preweanling period on later vulnerability towards drug
abuse.

Research is needed to investigate the possible

adverse consequences following methylphenidate treatment
during the preweanling period. . Of particular interest is

the question of whether early methylphenidate treatment

would increase later vulnerability towards drugs of abuse.
Therefore, for my thesis, I propose to determine

whether treatment with methylphenidate during the
preweanling period will alter the rewarding properties of
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morphine in adult rats.

To determine whether morphine is

rewarding, I will use a CPP paradigm.

In this paradigm, a

rat is given morphine, and it is restricted to a particular

compartment of the CPP apparatus.

On alternating days, the

rat is given saline, and it is restricted to a different
compartment.

The compartments of the CPP apparatus have

distinctive colors and odors.

In the proposed study, I will investigate the effects

of early methylphenidate exposure on the acquisition,
extinction, and reinstatement of morphine-induced CPP.

I

predict that rats given early methylphenidate exposure will

(1) spend a greater amount of time in the morphine-paired

environment than the saline exposed rats,

(2) that the

morphine-induced place preference will be harder to

extinguish in the methylphenidate pretreated rats than the
saline pretreated rats, and (3) that the morphine-induced
place preference will be more readily reinstated in the

methylphenidate pretreated rats than the saline pretreated
rats.

In investigating the extinction and reinstatement of

morphine-induced CPP, I will be able to determine the

consequences of early methylphenidate exposure on morphine
withdrawal and relapse.

I propose that methylphenidate

exposure during development-causes long-lasting neural
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alterations that have the potential to impact not only
vulnerability towards drug abuse, but also, vulnerability

towards drug relapse.

Should the results of my experiment

support my hypotheses, it will have implications for the
clinical use of methylphenidate in young children diagnosed

with ADHD.
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CHAPTER NINE
METHODS

Subjects

Subjects were 83 male and female rats of SpragueDawley decent, born and raised at California State

University, San Bernardino.

Rats were kept with the dam

until weaning, when they were placed into group cages with
same-sex littermates.

No more than one rat from each

litter was placed into a particular group.

The colony room

was maintained at 21-23°C and kept under a 12-hour
light/dark cycle.

Drugs

Methylphenidate hydrochloride was dissolved in saline
and injected intraperitoneally (ip) at a volume of 5 ml/kg

Morphine sulfate was also dissolved in saline and injected

subcutaneously (sc) at a volume of 1 ml/kg.

Both drugs

were purchased from Sigma Aldrich (St. Louis, MO).

In Vivo Drug Treatment

Starting at postnatal day (PND) 10, rats received
daily injections of saline or methylphenidate (2 or 5

mg/kg, ip, 5 ml/kg).

These daily injections continued for
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10 consecutive days (this age span is analogous to early
childhood in humans).

Conditioned Place
Preference Apparatus
Conditioning and testing were done in a T-shaped

chamber consisting of three compartments.

The two large

end compartments are adjacent to each other and separated
by a removable partition.

24 x 30 x 45 cm.

The two end compartments measure

The small compartment (the placement

chamber) projected out from the junction between the large
compartments.

cm.

The small compartment measured 24 x 10 x 45

A second removable partition enabled rats to enter

either of the large compartments from the placement
chamber.

varied.

The odor, flooring, and color of each compartment
One of the large end compartments had white walls,

wire mesh flooring, and pine bedding.

The other large

compartment had black walls, metal rod flooring, and cedar
bedding.

The placement chamber had a solid wood floor and

was painted gray.
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Conditioned Place
Preference Procedure

Preconditioning Day
On Day 1, following acclimation to handling, a total

of 83 (n = 6 per group) 60-day-old rats were put into the
placement chamber of the apparatus.

After rats entered

either the black or white compartment, access to the
placement chamber was blocked, and rats were allowed 15 min

of free access to both large end compartments.

Preferences

for the black and white compartments were determined for
each rat at the end of the day. No injections were given on

the preconditioning day.
Conditioning Phase

There were 8 daily conditioning sessions (Days 2-9)

lasting 30 min each.

On each conditioning day, rats either

(a) received an injection of morphine (1 or 5 mg/kg, sc, 1

ml/kg) and placed in their non-preferred compartment, or
(b) received an injection of saline and placed in their

preferred compartment.

Injections of morphine and saline

were alternated daily, and the initial drug order was

counterbalanced between groups.
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Test for Induction of
Morphine-Induced
Conditioned Place
Preference

On the test day (Day 10), rats were put in the
placement chamber, and given free access to the large end
compartments for 15 min.

The CPP procedure was videotaped,

and time spent in each compartment was scored by
experimenters who were blind to treatment conditions.

Induction of CPP was determined by comparing total time
spent in the non-preferred compartment with total time
spent in the preferred compartment on Induction Test Day.

Similar to the preconditioning day, rats received no

injections on the test day.
Extinction Phase

For 8 consecutive days (Days 11-18), all rats were
given daily injections of saline.

Each rat underwent 4

saline sessions in the previously drug-paired compartment
and 4 saline sessions in the previously saline-paired

compartment.

Placement in the previously drug-paired

compartment and previously saline-paired compartment were

alternated daily.

86

Test for Extinction of
Morphine-Induced
Conditioned Place
Preference
On Day 19, a test for extinction was performed

following the same procedure used in the testing for
induction of CPP.

Rats were put in the placement chamber,

and given free access to the large end compartments for 15
min. Extinction of CPP was determined by comparing total

time spent in the drug-paired compartment with total time
spent in the saline-paired compartment on Extinction Test

Day.

Test for Reinstatement
of Morphine-Induced
Conditioned Place
Preference
On Day 20, rats received a priming injection (1 mg/kg)
of morphine.

Fifteen min later, rats were allowed free

access to the two compartments for 30 min.

in each compartment was recorded.

The time spent

Reinstatement of CPP was

determined by comparing total time spent in the drug-paired
compartment with total time spent in the saline-paired

compartment on Reinstatement Test Day.
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Experimental Design and
Statistical Analysis
The study was a 2 x 3 x 2 experimental design.

Sex had

Drug pretreatment had 3 levels:

2 levels: male or female.

0, 2, or 5 mg/kg methylphenidate.

levels: 1 or 5 mg/kg morphine.

Drug treatment had 2

Litter effects were

controlled by treating litter as a random factor in all

analyses.
Body Weight
Preweanling weights during the 10 days of
methylphenidate drug administration were analyzed using a
2 (sex) x 3 (pretreatment) x 10 (day) between-subjects

ANOVA.

Adult weights on the 1st day of CPP testing were

analyzed using a 2 (sex) x 3 (pretreatment) between-

subjects ANOVA.

Tukey tests were used as a post hoc

analysis to determine the differences between the 3

pretreatment groups.
Preconditioning Compartment
Preference
Preconditioning room preference was analyzed using a

3(pretreatment) x (compartment). within-subjects ANOVA that
compared total time spent in the black compartment with
total time spent in the white compartment.
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Induction of Conditioned
Place Preference
Induction of CPP was analyzed using a 3(pretreatment)

x (post treatment) within-subjects ANOVA that compared
total time spent in the drug-paired compartment with total

time spent in the saline-paired compartment for each rat.
Extinction of Conditioned
Place Preference
Extinction of CPP was analyzed using a 2 (sex) x 3

(pretreatment) x 2 (post treatment) between-subjects ANOVA
that compared total time spent in the drug-paired
compartment with total time spent in the saline-paired
compartment between the different treatment groups.

Tukey

tests were used as a post hoc analysis to determine the

differences between the 3 pretreatment groups.
Reinstatement of
Conditioned Place
Preference

Reinstatement of CPP was analyzed using a 2 (sex) x 3

(pretreatment) x 2 (post treatment) between-subjects ANOVA
that compared total time spent in the drug-paired
compartment with total time spent in the saline-paired
compartment between the different treatment groups.

Reinstatement was analyzed in 3 time blocks: 1st 15 min, 2nd
15 min and 30 min.

Tukey tests were used as a post hoc
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analysis to determine the differences between the 3

pretreatment groups.
Locomotor Activity on the
First and Last Day of
Morphine Exposure
Locomotor activity on day 1 and day 8 of conditioning

was analyzed using separate 2 (sex) x 3 (pretreatment) x 2

(post treatment) between-subjects ANOVA.

(pretreatment) x 2 (post treatment) x 2

A 2 (sex) x 3
(day) repeated

measures analysis was also done to compare 'locomotor
activity between the first and last day of drug exposure
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CHAPTER TEN
RESULTS

Preweanling Body Weights
Preweanling body weights were not differentially
affected by methylphenidate pretreatment nor did they
differ by sex.

There was a significant, increase in body

weight from the first day of injections (PND 10) to the

last day of injections (PND 19) with rats weighing

significantly more with each additional day (see Figure 1)
(Day main effect, F(9,216)=1984.47, p < .01, Tukey tests).

Adult Body Weights

At PND 61, males weighed significantly more than
females regardless of drug pretreatment (Sex main effect,
F( 1,24)=362.04, p < .01).

Interestingly, rats treated with

5 mg/kg methylphenidate were significantly heavier than
rats treated with saline or 2 mg/kg methylphenidate.

Further analyses, however, showed that this effect was only
apparent in females (see Figure 2)

(Sex x Pretreatment

interaction, F(2,24)=3.81, p < .05, Tukey tests).
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Injection day

Rats were injected with methylphenidate (0, 2, or 5 mg/kg)
from PND 10 to PND 19. Body weight was not differentially
affected by methylphenidate pretreatment.
Figure 1. Mean Preweanling Body Weights During 10 Days of
Methylphenidate Injections
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Adult Weights

400'

I Males

Females

a Indicates a significant difference between male and female
rats.
b Indicates a significant difference in female rats
pretreated with 0 mg/kg methylphenidate.
Figure 2. Mean Body Weights (+ SEM) on the First Day of
Conditioned Place Preference Training (PND 61)
for Male and Female Rats Previously Exposed to
Methylphenidate (0, 2, or 5 mg/kg) from PND 10 to
PND 19

Initial Chamber Preference
Regardless of drug pretreatment, rats showed an

initial preference for the black compartment over the white
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compartment (see Figure 3)

(Room main effect,'

F(16,40)=2.19, p < .05).
Initial Preference Day

Black

White

Compartment

Rats were previously exposed to methylphenidate (0, 2, or 5
mg/kg) from PND 10 to PND 19.
a Indicates a significant difference from time spent in the
white compartment.
Figure 3. Mean Time Spent in Each Compartment (± SEM) on
the Initial Preference Day (PND 60)

Induction of Conditioned
Place Preference
Rats given either 1 mg/kg or 5 mg/kg morphine

demonstrated induction of CPP, because rats spent more time
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in the drug-paired room as compared to the saline-paired
room (see Figure 4)

(Room main effect, F(l,17)=5.01, p <

No significant sex or pretreatment effects were

.05).

found.

Acquisition Test Day

700-i----------------------------------------------------600-

co

Saline-Paired

Drug-Paired

Compartment

Rats were given alternating daily injections of morphine (1
or 5 mg/kg) and saline on PND 61 to PND 68.
Data for the
drug-paired compartments were collapsed across the two
doses of morphine.
a Indicates a significant difference from time spent in the
saline-paired compartment.
Figure 4.. Mean Time Spent in Each Compartment (± SEM) on
the Induction Test Day (PND 68)
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Extinction of Conditioned
Place Preference
Methylphenidate pretreatment increased the time needed

to extinguish CPP, as rats treated with 5 mg/kg
methylphenidate were slower to extinguish than rats treated

with the low dose of methylphenidate or saline

(Pretreatment main effect, F(2,3)=812.93, p < .01, Tukey
tests).

Morphine dose also affected rate of CPP

extinction, because rats treated with 1 mg/kg morphine were
slower to extinguish than rats treated with 5 mg/kg
morphine (Post treatment main effect, F(l,3)=731.32, p <

.01).

However, the ability of the high dose

methylphenidate pretreatment (5 mg/kg) and the low dose
morphine conditioning treatment (1 mg/kg) to increase time

spent in the drug-paired room during extinction testing was
only significant for female rats (see Figure 5)

(Sex x

Pretreatment x Post treatment interaction, F(2,3)=237.84, p

< .01, Tukey tests).

Overall, CPP was harder to extinguish

in male rats (M=196.629 S, SEM=44.484) than in female rats
(M=180.804 S, SEM=39.140)

(Sex main effect, F(l, 3)=33.68, p

< .05) .
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Reinstatement of
Conditioned Place
Preference
During the first 15 min block on the reinstatement
test day, CPP was more readily reinstated in rats

pretreated with 5 mg/kg methylphenidate than rats
pretreated with 2 mg/kg methylphenidate or saline

(Pretreatment main effect, F(2,16)=9.57, p < .01, Tukey
tests).

In addition, there was a significant post

treatment effect such that CPP was more readily reinstated
in rats treated with 5 mg/kg morphine than rats treated
with 1 mg/kg morphine (Post treatment main effect,
F(l,16)=7.11, p < .05)

(see Figure 6).

There were no

significant effects found in the second 15 min block of

time.

For the entire 30 min block of time, CPP was more

easily reinstated in rats pretreated with 5 mg/kg

methylphenidate (M=1051.778 S, SEM=65.356) than rats

pretreated with 2 mg/kg methylphenidate (M=747.000 S,

SE=78.351) or saline (M=890.621 S, SEM=81.186)
(Pretreatment main effect, F(2,16)=4.29, p < .05, Tukey
tests).

There were no significant sex effects found during

reinstatement.
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Extinction Test Day
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Methylphenidate Pretreatment (mg/kg)

During extinction training (PND 69-PND 76), rats were
injected with saline and given alternating daily placements
in the black and white compartments.
a Indicates a significant difference from rats pretreated
with 2 mg/kg methylphenidate or 0 mg/kg.
b Indicates a significant difference from rats treated with
5 mg/kg morphine.

Figure 5. Mean Time (± SEM) Spent in the Drug-paired
Compartment on the Extinction Test Day (PND 77)
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Reinstatement Test Day
800'

1 mg/kg Morphine

5 mg/kg Morphine

0

2

5

Methylphenidate Pretreatment (mg/kg)
All rats were primed with a 1 mg/kg dose of morphine 15 min
prior to testing.
a Indicates a significant difference from rats pretreated
with 2 mg/kg methylphenidate or 0 mg/kg.
b Indicates a significant main effect from rats treated with
1 mg/kg morphine.
Figure 6. Mean Time (± SEM) Spent in the Drug-paired
Compartment on the Reinstatement Test
Day (PND 78)

Locomotor Activity
On the first day of morphine administration, rats
treated with 1 mg/kg morphine displayed more locomotor
activity than rats treated with 5 mg/kg morphine (Post

treatment main effect, F(l,3)=18.28, p < .05).
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Locomotor

activity did not differ between drug groups on the last day

of morphine administration.

Locomotor activity for rats

treated with 5 mg/kg morphine increased significantly from
the first drug exposure to the last drug exposure (see
Figure 7)
p < .05).

(Post treatment x Day interaction, F(l,3)=16.24,
This sensitization effect was not found for rats

treated with 1 mg/kg morphine.

Neither methylphenidate

pretreatment or sex affected locomotor activity of rats
during the CPP procedure.
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Locomotor Activity
1501 mg/kg Morphine

5 mg/kg Morphine

Exposure Day

During conditioning, rats were injected with either 1 or
5 mg/kg morphine.
a Indicates a significant difference from rats treated
with 5 mg/kg morphine on Day 1.
b Indicates a significant difference from rats treated
with 5 mg/kg morphine on Day 8.
Figure 7. 'Mean Line Crosses (± SEM) on the First and Last
Days of Conditioned Place Preference Conditioning
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CHAPTER ELEVEN
DISCUSSION

Effects of Preweanling
Methylphenidate Exposure on
Morphine-Induced Reward
in Early Adulthood

Methylphenidate pretreatment has been found to
significantly alter the rewarding properties of drugs in
rats (Achat-Mendes et al., 2003; Anderson et al., 2002;

Brandon et al., 2001).

In the present study, it was found

that methylphenidate exposure during the preweanling period
affects morphine-induced CPP.

Three original predictions

were made regarding the effect of methylphenidate

pretreatment on morphine-induced CPP.
hypothesized that:

Specifically, it was

(1) rats given early methylphenidate

exposure would spend a greater amount of time in the

morphine-paired environment than saline-exposed rats;

(2)

the morphine-induced place preference would be harder to
extinguish in methylphenidate-pretreated rats than saline-

pretreated rats; and (3) the morphine-induced place
preference would be more readily reinstated in

methylphenidate-pretreated rats than saline-pretreated
rats.

The prediction that rats pretreated with

methylphenidate would spend a greater amount of time in the
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morphine-paired environment was not supported, because the
induction of CPP did not differ among the methylphenidate

pretreatment groups.

It was also predicted that morphine-

induced place preference would be slower to extinguish in
methylphenidate-pretreated rats than saline-pretreated

rats.

This hypothesis was supported.

Rats pretreated with

the high dose of methylphenidate were slower to extinguish
than rats pretreated with the low dose of methylphenidate

or saline.

Lastly, it was predicted that morphine-induced

place preference would be more readily reinstated in

methylphenidate-pretreated rats than saline-pretreated
rats.

This hypothesis was supported during the first 15

min block of time, because CPP was more readily reinstated
in rats pretreated with the high dose of methylphenidate
than rats pretreated with the low dose of methylphenidate

or saline.

The present results indicate that preweanling

methylphenidate exposure has a long-term impact on the

rewarding properties of morphine.

Specifically,

preweanling methylphenidate administration appears to

increase the rewarding value of morphine.

Past research

supports the notion that early methylphenidate exposure

impacts drug reward (Achat-Mendes et al., 2003; Anderson et
al., 2002; Brandon et al., 2001).
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However, none of the

prior studies administered methylphenidate during the

preweanling period.

Rather, methylphenidate was

administered during the pre-adolescent and adolescent
stages of development.

The reports examining the effects

of adolescent methylphenidate exposure on drug reward are
inconclusive (Achat-Mendes et al., 2003).

For example,

pretreating 4-week-old rats with methylphenidate (2 mg/kg)
caused an increase in cocaine self-administration two weeks

after methylphenidate treatment (Brandon et al., 2001).

In

contrast, pretreating rats with methylphenidate (2 mg/kg)
on PND 20-35 reduced the rewarding effects of cocaine on
PND 60 (Anderson et al., 2002).
Methylphenidate may impact drug reward differently

depending on the developmental stage at which it is
administered.

Interestingly, exposure to methylphenidate

during the adolescent period appears to increase drug

responsiveness, while exposure during the earlier pre
adolescent period reduces responsiveness to later
psychostimulant administration (Anderson et al., 2002;

Brandon et al., 2001).

The developmental stage at which

methamphetamine is administered also impacts long-term

neurotoxic effects, with developing rats failing to exhibit

the characteristic pattern of long-term methamphetamine
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neurotoxicity (Cappon et al., 1997).

Therefore, it would

not be surprising if the developmental stage during which
amphetamines, such as methylphenidate, are administered has

a differential effect on drug reward.
Body weight measurements provide additional evidence

that methylphenidate's effects vary according to age.

When

administered on PND 10 - PND 20, methylphenidate and saline
did not differentially affect body weight (See Figure. 1) .,

Not only did methylphenidate not inhibit weight gain during
the preweanling period but on the first day of CPP testing

(PND 61), females pretreated with the higher dose (5 mg/kg)
of methylphenidate weighed more than females pretreated

with the lower dose of methylphenidate (2 mg/kg) or saline.
While this finding contradicts research showing that

methylphenidate inhibits weight gain (Spencer et al., 1996;

Vincent, Varley & Legger, 1990), most of these studies have
administered methylphenidate during later stages of

development.

This indicates that there may be

developmental differences in the way methylphenidate
impacts body weight.

The results revealed a methylphenidate dose effect,
with the higher dose of methylphenidate (5 mg/kg) causing

an increase in the rewarding value of morphine.
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Rats

pretreated with the high dose of methylphenidate (5 mg/kg)
were slower to extinguish as compared to rats pretreated

with the low dose of methylphenidate (2 mg/kg).

Similarly,

CPP was more readily reinstated in rats pretreated with the
high dose of methylphenidate than rats pretreated with the

low dose.

In fact, the low dose of methylphenidate had no

effect on reward at ail.

This suggests that higher doses

Of methylphenidate are more likely to alter reward
mechanisms in preweanling brain.

However, rats pretreated

with 2 mg/kg methylphenidate during adolescence
self-administered cocaine at a higher rate than rats
pretreated with saline (Brandon et al., 2001). This

suggests that a low dose of methylphenidate does impact
reward during later stages of development.

It should be

noted that while 5 mg/kg is considered a high therapeutic
dose, young children are often prescribed a higher doses of
methylphenidate than adolescents and adults (Volkow et al.,

2001).
One of the major differences between the present study
and previous studies is that all other studies assessed

methylphenidate's impact on the rewarding properties of

cocaine, while we examined morphine CPP.

This has

particular significance when discussing the role of the
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mesolimbic dopamine system in reward.

It is generally

acknowledged that dopamine receptors in the mesolimbic

system mediate reward (Ikemoto & Panksepp, 1999).

Drugs of

abuse share the ability to selectively stimulate dopamine

release within the mesolimbic system (Ikemoto & Panksepp,
1999).

Methylphenidate causes long-lasting neural

alterations to the mesolimbic dopamine system, thereby
impacting the rewarding properties of cocaine (Achat-Mendes

et al., 2003; Anderson et al, 2002; Brandon et al., 2001).
By demonstrating that methylphenidate exposure can also
impact the rewarding properties of morphine, we provide

further evidence that the mesolimbic dopamine system

mediates reward.

And more importantly, this provides

further evidence that methylphenidate exposure causes
neural alterations to the mesolimbic dopamine system.
The neural mechanisms underlying amphetamine's ability

to alter the mesolimbic dopamine system and impact reward
are not completely understood.

But I have hypothesized

that dopamine D2 receptors play a key role.

Exposure to

amphetamine reduces the number of dopamine D2 receptor
binding sites (Bennett et al., 1998; Chen et al., 1999;

McCabe et al., 1987; Volkow et al., 2001).

Furthermore,

dopamine D2 receptor levels are predictive of the rewarding
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properties of drugs of abuse.

Lower levels of D2 receptors

are associated with increased drug-liking, pleasure, and
euphoria (Laruelle et al., 1995; Volkow et al., 1999).

Thus, it is possible that methylphenidate, like other
amphetamines, decreases the number of dopamine D2 receptor
binding sites, with this effect being greatest at higher

doses.

This reduction in dopamine D2 receptor binding sites

may be responsible for an increase in the rewarding

properties of drugs of abuse following methylphenidate

exposure.
In the present study, methylphenidate impacted the
extinction and reinstatement of morphine-induced CPP while

not affecting induction.

Interestingly, similar results

were obtained when mice were pretreated with

methylphenidate (10 mg/kg) from PND 26-32 and tested for

the induction and reinstatement of cocaine-induced CPP

(Achat-Mendes et al., 2003).

While pre-exposure to

methylphenidate initially impaired the acquisition of

cocaine-induced CPP in adulthood, reinstatement of cocaine-

induced CPP was greater in mice pretreated with
methylphenidate.

Taken together, these results suggest

that methylphenidate-induced neural adaptations in the

reward system are slow to develop.
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Ultimately, both

studies suggest that early methylphenidate exposure results
in an enhanced response to the rewarding • effects of drugs.

Implications for Use of
Methylphenidate for the
Treatment of Attention-Deficit/
Hyperactivity Disorder in
Early Childhood with Regard '
to Vulnerability Towards •Drug Abuse
The present study indicates that preweanling
methylphenidate exposure increases the rewarding properties

of drugs of abuse.

It has been found that methylphenidate

exposure during the preweanling period causes enduring
changes in the neurobiology of brain reward systems,
thereby impacting drug reward.

The preweanling period in

rats is analogous to early childhood in humans.

Therefore,

our findings have implications for use of methylphenidate
for the treatment of ADHD in early childhood.

The age at

which stimulant treatment is given seems to be an important

factor, presumably because of the way it impacts the

maturation of the dopamine system (Robbins, 2002).

During

early childhood, the brain dopamine system is still

maturing (Solanto, 1998).

Therefore, stimulant medication,

such as methylphenidate, may affect the brain of a young

child differently than the brain of an adolescent or adult.
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Our findings suggest that preweanling methylphenidate

exposure does impact the reward system, since it was found
that methylphenidate administration increases the rewarding

value of drugs of abuse.

These findings imply that

stimulant treatment during early childhood may act as a

risk factor for drug-seeking and drug-taking in adulthood.

Thus, one may be more susceptible to drug addiction because
drugs of abuse become more rewarding following stimulant

treatment in early childhood.
Our study found methylphenidate to impact extinction

and reinstatement of morphine-induced CPP.

The

extinction/reinstatement paradigm is often used as a model

of relapse (Fuchs et al., 1998).

By using an

extinction/reinstatement paradigm in the study, we were
able to investigate the consequences of early

methylphenidate exposure on morphine withdrawal and
relapse.

Our findings suggest that methylphenidate

exposure during early childhood not only increases

vulnerability towards drug abuse, but also increases
vulnerability towards drug relapse.

This suggests that the

neural alterations triggered by methylphenidate exposure
during early childhood are long-lasting and may potentially

persist for many years.
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Animal research assessing the effects of preweanling
methylphenidate exposure on vulnerability towards drug

abuse is sparse.

Further research is needed to ascertain

how neuroadaptations caused by stimulant exposure are

affected by dose, age at exposure, and treatment duration
(Anderson et al., 2001).

In addition, further molecular

work is needed to ascertain which neural substrates are
responsible for methylphenidate's impact on drug reward,

with special attention given to measuring dopamine D2

receptor levels.

Given the findings of this study, it is

important to consider the possibility of adverse effects of
stimulant medication on the developing brain.

There is a

lack of research within the human population assessing the
use of stimulant medication for preschool-aged children.

This is particularly important because preschool-aged

children diagnosed with ADHD may be treated with stimulants
for many years (Connor, 2002).

Our study suggests that

particular attention should be given to further

investigating the possibility that stimulant treatment
during early childhood increases one's vulnerability
towards drug abuse.

It is hoped that additional clinical

research will examine the balance between the short-term
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expediency of methylphenidate treatment and the longer-term
risk of promoting future drug abuse (Robbins, 2002).
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